Innovative biomedical applications using hybrid nanoparticles by Kim, Jason Sung
  
 
 
 
INNOVATIVE BIOMEDICAL APPLICATIONS USING HYBRID NANOPARTICLES 
 
 
 
 
Jason Sung Kim 
 
 
 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in 
partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Department of Chemistry. 
 
 
 
 
Chapel Hill 
2008 
 
 
 
 
 
 
Approved by: 
 
Professor Wenbin Lin 
 
Professor Cynthia K. Schauer  
 
Professor Holden H. Thorp 
 
Professor Rihe Liu 
 
Professor Teresa K. Tarrant 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2008 
Jason Sung Kim 
ALL RIGHTS RESERVED 
  
 iii 
 
 
 
 
 
 
ABSTRACT 
 
JASON SUNG KIM: Innovative Biomedical Applications Using Hybrid Nanoparticles 
(Under the direction of Wenbin Lin) 
 
 
Nanoparticle and metal-chelate technologies can be combined to create innovative 
hybrid materials with versatile functions for research and clinical purposes.  This dissertation 
addresses the novel use of hybrid inorganic/organic nanoparticles in biomedical applications, 
including early detection of autoimmune disease and cancer as well as purification of 
therapeutic proteins.  In an in vivo animal model of rheumatoid arthritis (RA), fluorescent 
nanoparticles coated with a magnetic resonance imaging (MRI) contrast enhancing metal-
chelate are used for cell specific trafficking of monocytes, which correlate with disease 
activity.  Metal-chelate derivatized magnetic nanoparticles isolate tagged proteins, potential 
cancer therapeutics, from impurities generated from bacterial and mammalian cell expression 
systems.  The novel applications of hybrid magnetic nanoparticles pursued in this dissertation 
have the ability to translate into new and more sensitive strategies to treat patients with 
chronic disease.  
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CHAPTER 1 
 
HYBRID NANOMATERIALS FOR BIOMEDICAL APPLICTIONS: FUNDAMENTALS, 
STRATEGIES, AND HISTORICAL OVERVIEW  
 
 
 
1.1  Introduction to hybrid nanomaterials 
Inorganic nanostructures such as II-VI semiconducting quantum dots and 
superparamagnetic Spinel ferrite nanoparticles have attracted great interest from the 
scientific, engineering, and medical communities because of their strongly size- and shape-
dependent physical properties.1-5  The past two decades of intensive research has led to 
numerous highly reliable and reproducible synthetic methodologies for inorganic 
nanostructures with well-defined and nearly identical properties such as size, shape, 
composition, crystal structure and surface properties.  The field of organic polymer colloidal 
particles is even more mature,6-12 as evidenced by the commercial availability of numerous 
polymeric nanoparticles.  Reverse microemulsion polymerization and precipitation 
polymerization have, for example, allowed the synthesis of many monodisperse polymeric 
colloidal particles.  In contrast to the inorganic nanostructures and polymer colloidal 
particles, relatively little has been done on organic/inorganic hybrid nanomaterials.   
By merging the unique attributes of both soft organic and hard inorganic components, 
organic/inorganic hybrid nanomaterials offer many interesting characteristics that do not 
exist in either inorganic nanostructures or polymer colloidal particles alone.  They can not 
only possess some of the unique properties of inorganic nanostructures as a result of the size-
 2 
 
dependent behaviors but also allow synthetic manipulations of the organic components with a 
molecular precision.  The modular synthetic procedures for organic/inorganic hybrid 
nanomaterials further allow systematic fine-tuning of their properties for specific 
applications.  Indeed, such an amalgam of hybrid materials and nanotechnology has already 
opened the door for a wide range of applications across multiple fields of science, 
engineering, and medicine.  For example, the synergistic interactions between adsorbed 
ruthenium complex antenna and titania nanoparticles have led to the design of Grätzel solar 
cells that have the potential to revolutionize solar energy utilization.13-16 In heterogenous 
asymmetric catalysis, Lin et al. has developed a magnetically recoverable iron oxide hybrid 
nanoparticle-supported chiral ruthenium (II) catalyst for the synthesis of chiral secondary 
alcohols.17  The applications of organic/inorganic hybrid nanomaterials in other fields (such 
as biological sensing, biomedical imaging, and catalysis) have also been recently 
demonstrated.18-22 This chapter surveys some of the latest developments in the design and 
applications of hybrid nanomaterials in the biomedical and biological fields.   
 
1.2 Hybrid nanomaterials as MRI contrast agents 
Magnetic resonance imaging (MRI) is a diagnostic tool that relies on the same 
mechanism as the commonly used nuclear magnetic resonance (NMR).  Based on the 
differentiated water proton signals, MRI provides images of anatomical structures and other 
physiological environments with an excellent spatial resolution.23  A patient is placed within 
a homogenous, static magnetic field B0 of an MR scanner to resonate nuclear spins at a 
determined frequency.  The hydrogen nuclei of water protons precess at the Larmor 
frequency (ωL) around and directed relative to B0 (Figure 1.1).  Possessing a ½ spin, the 
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hydrogen nuclei have two quantum mechanically allowed directions that correspond to the 
energy levels of the nuclei.  A radiofrequency pulse (B1) sequence, perpendicular to B0, is 
used to excite the proton spins, which changes the net magnetization (M).  The Boltzmann 
distribution shows that slightly more spins occupy the lower energy state (spin up) than the 
higher energy state (spin down), ultimately leading to the vector M.24  As the spins relax back 
to their original thermal equilibrium, the electromagnetic signals are recorded and 
transformed to three dimensional images.   
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A)  
B)  
C)  D)   
E)  
Figure 1.1  Schematic representation of hydrogen nuclei before and after placement within a 
magnetic field B0. A) Nuclei are randomly oriented until application of magnetic field 
induces alignment.  B) The hydrogen nuclei precess around B0 at the Larmor frequency, ωL, 
the net magnetization vector M is a result of more spins occupying the lower energy state 
(spin up).  C)  The net magnetization before electromagnetic radiofrequency pulse.  D) The 
radiofrequency pulse generates a magnetic field B1 that causes M to flip perpendicular to B0, 
while revolving around the B0-axis.  E)  The removal of the radiofrequency pulse allows the 
relaxation of M to the original state. 
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MR image contrasts result from the inherently variable levels of water present in 
different tissues and water environments.  For example, the higher water content of the brain 
leads to differences in MR contrast compared to muscle tissue of lower water content.  The 
longitudinal relaxation time constant (T1) and the transverse relaxation time constant (T2) of 
the proton spins are the most significant factors that determine the proton signal intensity 
from a particular tissue.  T1 describes the spin-lattice relaxation of M returning to 
equilibrium after B1 is removed.  Here, random motion of lattice molecules fluctuates at the 
Larmor frequency to increase relaxation to the lower energy state.  T2 describes the spin-spin 
relaxation returning to zero as random motion of molecules resonating at the same frequency 
leads to reduction of phase coherence.   
Further, longitudinal relaxation rate can be enhanced by the addition of a 
paramagnetic metal and is described by, 
 
R1obs  = R1pis +R1pos + R1w. 
 
R1pis represents the contribution due to exchange of water molecules coordinating to the inner 
sphere of the metal ion, while R1pos represents the contribution due to water diffusion into to 
outer sphere of the metal ion.  These contributions are added to the water relaxation rate in 
the absence of the paramagnetic metal, R1w, to determine the observed longitudinal relaxation 
rate R1obs.  Figure 1.2 schematically represents the two relaxation mechanisms.  The 
equation, 
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R1pis = 
(c x q) 
________ x
1 
_____________ 
 
55.6 
 
(TH1M + τm) 
 
describes the inner sphere relaxation rate.  The molar concentration of the paramagnetic 
metal ion is c.  The number of water molecules coordinated to the metal ion is q, with τm as 
the mean residence lifetime.  TH1M is the longitudinal relaxation time of each coordinated 
water molecule which is described in clinical settings as,   
 
 
TH1M = 
(2 γ12 g2 μ B 2) 
________________ S(S + 1) 
[(7 τc2) 
_________________ +
(3 τc1)] 
________________  . 
 
(15 rGdH6) [(1 + ω S 2τc23) (1 + ω I 2 τc12)] 
 
 
Here, γ1is the nuclear gyromagnetic factor, g is the electron g-factor, μ B is the Bohr 
magneton, rGdH is the electron spin-proton distance, S is the spin of the paramagnetic ion, ω S 
is the electron Larmor frequency, ωI is the nuclear Larmor frequency, and τc is the correlation 
time.  The correlation time is described by,  
 
1 
__ =
1 
__ +
1 
__ +
1 
__ ; i = 1,2 
  τc 
 
τm
 
τr
 
τci
 
 
where τm is the water proton mean residence time, τr is the reorientational correlation time, 
τc1 is the longitudinal electron spin relaxation time, and τc2 is transverse electron spin 
relaxation time.  Many groups have attempted to alter relaxivities by adjusting parameters, 
such as q, τm , τr, and rGdH.25, 26 
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Figure 1.2 Schematic representation of paramagnetic Gd(III) interaction with water 
molecules and some of the main parameters affecting relaxation. 
 
By administering contrast agents, the T1 and T2 parameters can be manipulated to 
gain greater image contrast of specific tissues.  This is particularly important when imaging 
diseases where the abnormal disease tissue has similar water content to the normal tissue.  
Highly paramagnetic Gd(III)-chelates have been used to enhance water proton longitudinal 
relaxation, which results in increased (hyper-intense) MR signals.  Approximately half of 
clinical MR images are performed with the aid of Gd(III)-chelate contrast agents to detect 
conditions such as organ perfusion, blood/brain barrier abnormalities, and aberrant kidney 
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function.27  Alternatively, a contrast agent can be used to enhance water transverse 
relaxation, leading to reduced (hypo-intense) MR signals.   
MRI is intrinsically much less sensitive than other imaging techniques such as 
positron-emission tomography (PET) or single photon-emission computed tomography 
(SPECT).  As a result, it remains a great challenge to develop MR contrast agents that 
specifically target the diseased tissues.  The advances in molecular and cell biology have 
uncovered a large number of biomarkers that are overexpressed on cell surfaces of a number 
of diseases.  A straightforward strategy is to selectively and specifically delivering imaging 
contrast agents by conjugation to affinity molecules to the biomarkers.  Such an approach has 
been successfully used to design target-specific PET and SPECT contrast agents by tagging 
radionuclides or their complexes with antibodies or other cell-targeting molecules.28-33  
However, Gd(III)-chelates at sub-mM concentrations are needed to provide sufficient MR 
image contrasts.  This concentration is several orders of magnitude higher than that of 
overexpressed biomarkers.34  There is thus a urgent need of synthetic strategies that allow for 
the delivery of a very large payload of Gd(III) chelates with each cell-targeting molecule.   
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Figure 1.3 Examples of low molecular weight Gd(III) complexes clinically used for contrast-
enhanced MRI. 
 
Nanometer-scale materials have the ability to carry high payloads while maintaining 
the ability to move through physiological systems.  For MRI contrast enhancement, these 
materials continue to require paramagnetic metals ions such as Gd(III), necessitating the 
development of hybrid cargo platforms.  The many nanomaterial strategies – including 
superparamagnetic iron oxide, microemulsions, liposomes, and hybrid silica nanoparticles – 
will be discussed throughout this section.  
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1.2.1 Superparamagnetic iron oxide nanoparticles 
Superparamagnetic iron oxide (SPIO) nanoparticles were initially shown to improve 
the detection of focal liver lesions over the Gd(III)-DTPA enhanced MRI scans, leading to 
their FDA approval for clinical use in 1996,35-37 SPIOs are ferrites composed of γ-Fe2O3 and 
Fe3O4 magnetite phases that can be prepared by a variety of methods, 1,38 most commonly by 
oxidative coprecipitation or thermal decomposition.  Superparamagnetic properties of SPIOs 
allow for zero magnetization in the absence of an external magnetic field and the ability to 
efficiently relax proton spins for MRI.  The highly efficient spin relaxation rates, longitudinal 
r1 and transverse r2, are achieved through the dipole interaction between the surrounding 
water protons and the high magnetic moment of the superparamagnetic particles.38  The large 
magnetization difference between the non-homogeneous distribution of SPIOs gives rise to 
local field gradients, further enhancing relaxation of proton spins.  Superparamagnetic 
species experience this phenomenon more significantly than individual paramagnetic 
Gd(III)-complexes, generating large increases in r2 when moving to increased magnetic 
fields.  At low concentrations, T1-effects can be detected, producing signal enhancement 
(bright images).  In general, the T2-effects dominate and result in large enhancements of 
signal void (darkening of images).  Higher detection sensitivity has been reported by utilizing 
sequences designed for T2-weighted imaging.39   
As pioneered by Ralph Weissleder, recent efforts have been focused on developing 
SPIO/biomolecule conjugates for target-specific MR imaging of cancers and other diseases.  
In one formulation, superparamagnetic iron oxide nanoparticles were coated with cross-
linked dextran, a naturally occurring glucose-based polysaccharide capable of complexing 
iron metal ions.  Several variations of the formulation exist and are called cross-linked iron 
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oxide (CLIO), ultrasmall superparamagnetic iron oxide (USPIO), Combidex®, or 
Ferumoxtran in the basic science and clinical literature.  Combidex® is composed of 
materials on the generally regarded as safe (GRAS) list and has received an approvable letter 
by the FDA (subject to certain conditions).  CLIO has been extensively used to image 
diseases in animals and humans, such as cancers or arthritis, as well as molecular biological 
processes.    
The surface modification with dextran that is crosslinked with epichlorohydrin is of 
key importance to achieve longer blood circulation times.  Further, the dextran can be 
chemically modified for conjugation of targeting molecules.40  Often, the dextran coated iron 
oxide nanoparticles can be used without any further functionalization to show image 
enhancement of disease states.  Due to the dextran stealth capabilities from the 
reticuloendothelial system (RES), signal void in the circulation can be detected due to the T2 
relaxation of the water protons.  Upon capture, the CLIO contrast enhancement can image 
abnormalities of the RES.  Weissleder showed such imaging capabilities in a clinical study of 
eighty prostate cancer patients41 as well as other diseases21, 41-45. The CLIO was shown to be 
lymphtrophic and could be effectively used to image nodal abnormalities that were otherwise 
undetectable.   
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Figure 1.4 Dextran coating of iron oxide nanoparticles are cross-linked by epichlorohydrin 
and amine terminated by ammonia to form hybrid nanomaterial MRI contrast agents with 
surface functionalization moieties. 
 
The cellular events involved in inflammation has led to the study of leukocyte action 
in arthritis46 and arteriosclerosis47, 48.  Particularly, monocytes and macrophages have 
emerged as a highly active set of cells in the inflammatory process.  Adoptive transfer studies 
have been presented as an additional use for CLIO nanoparticles for imaging cellular 
pathogenesis of autoimmune diseases.  Specifically, monocytes and T-cells were loaded ex 
vivo before allowing migration to disease sites.49-53  CLIO can also be used to detect analyte 
concentrations within tissue through action as a magnetic switch that can form reversible 
cluster assemblies.  At low glucose concentrations, concavalin-A is multivalently bound by 
glucose-derivatized CLIO to form larger aggregations that can be detected by T2 changes.54  
Additional CLIO systems based upon this T2-effect magnetic switch concept have been used 
to detect changes due to enzymatic activity on peptide sequences20 and oligonucleotides.55 
The dextran coating can be chemically modified and used to conjugate affinity molecules to 
enable the iron oxide nanoparticles to target and report the presence of disease tissue.  
Peptides and proteins have been used as functional conjugates with these nanoparticles to 
image prostate, hepatic, splenic, and glial neoplasia.41, 43, 56-61 Conjugated to E-selectin or 
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VCAM-1, CLIO detects endothelium specific proteins to monitor tumor angiogenesis.40, 62  
Apoptotic cells can also be detected when the CLIO particles are functionalized with 
Annexin V, a calcium dependant protein that has high affinity for the phosphatidylserine 
apoptosis marker in the cell membrane.19, 22, 63-66  These recent targeted iron oxide based 
contrast agents have progressed significantly from the fibrin-targeted CLIO that utilized the 
high availability of thrombin involved in blood coagulation.67  Though extensively studied 
and considered relatively mature, the iron oxide MR contrast agents continue to be the 
trailblazer in biomedical imaging.   
 
1.2.2 Multimodal perfluorocarbon microemulsion contrast agents 
Wickline and Lanza have devoted immense efforts toward preparing MRI contrast 
agents using oil-in-water microemulsion technology.68-71  Individual emulsion nanoparticles, 
approximately 250 nm in diameter, are formed with a perfluorocarbon core surrounded by a 
monolayer lipid shell.  The particles can be synthesized by emulsification of the 
perfluorodichlorooctane, safflower oil, and glycerin with preformed microemulsions.70  
While stabilizing the nanoparticle, the lipid can also be designed to carry extraordinarily high 
payloads of metal centers, up to 90,000 Gd(III) chelates per microemulsion nanoparticle.  
These Gd-containing nanoparticles possess extremely large MR relaxivities on per particle 
basis,72 and provide an ideal platform for conjugation to affinity molecules for target-specific 
imaging of various diseases.   
Targeting molecules can also be incorporated into the lipid layer to create a highly 
modifiable surface capable of directing these particles to specific sites.  Ligands for 
overexpressed disease biomarkers that have been used for this material ranges from small 
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molecules,73 integrins,74-76 fibrin,77, 78 and antibodies.79, 80  The targeted derivatives of the 
perfluorocarbon-lipid nanoparticles were used extensively to image cardiovascular structures 
and disorders, such as arterosclerosis.68, 69, 71, 81, 82  Targeted imaging of neovascularization in 
atherosclerosis could be accomplished through aνβ3-integrin modified perfluorocarbon 
microemulsion nanomaterials.76, 83  In the past few years, these nanoparticulate MRI contrast 
agents have been used to detect tumors and angiogenesis.84-87   
The perfluorocarbon core also allows for the unique capability of an additional MRI 
probe using the 19F signal.  19F MRI is an advantageous imaging tool because the magnetic 
resonance sensitivity is nearly as high as 1H (83%), the low abundance of endogenous 19F in 
biological systems, and the 100% natural abundance of 19F isotope.88  The perfluorocarbon 
emulsions encapsulated by lipid-surfactant monolayers have been used to prepare MRI 
contrast agents with high 19F payloads.  The perfluorocarbon-based microemulsion 
nanoparticles developed by Wickline and Lanza have demonstrated capabilities for target-
specific Gd(III) enhanced MR imaging but also shown multimodalities that further expand 
the utilities of this novel class of nanomaterials in early diagnosis of a variety of diseases.   
 
 
 
Figure 1.5 Dual 1H/19F MR imaging of thrombus in a human carotid endarterectomy: (a) 
Optical imaging showing moderate luminal narrowing, several atherosclerotic lesions and 
areas of calcification, (b) 19F projection image acquired at 4.7T at the same location showing 
high signal enhancement due to perfluorocarbon nanoparticles, (c) 1H image with false color 
overlay of quantified 19F image.  (Images have been used with permissions from reference 89.) 
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1.2.3 Liposomes 
Liposomes, first discovered over 40 years ago, are vesicles formed from amphiphiles 
such as phospholipids.  The interaction of the amphiphilic molecules with each other and the 
surrounding environment induces the formation of a lipid bilayer structure that is spherical in 
shape.  Due to their cargo carrying capacity, liposomes have been widely explored for drug 
delivery.  With the ability to encapsulate and protect a variety of therapeutics that may be 
unstable or poorly soluble in physiological systems, the efficiency of liposomes in drug 
delivery is believed to result from membrane bilayer fusion with the target cell membrane or 
via endocytosis.  In cell culture, liposomes are actively used and commercially available for 
transfection of DNA to transform a host cell. 
 
Amphiphilic Molecule
Hydrophobic Tail
Hydrophilic Head
Lipid Bilayer
Aqueous Solution
 
Figure 1.6 Schematic representation of liposome: Self-assembly of amphiphilic molecules in 
aqueous solution forms a lipid bilayer containing spherical vesicle. 
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Gadolinium-labeled liposomes90-96 were prepared by modifying the structure of the 
amphiphiles.  Gd(III) was coordinated to a DTPA chelator incorporated into the hydrophilic 
head group.  The lipid bilayer composition is easily modifiable, as the paramagnetic Gd(III) 
containing amphipathic molecules could be incorporated into preexisting liposome designs 
composed of egg lecithin and cholesterol.  The first Gd(III)-containing liposomes, tested by 
imaging the liver and spleen of normal Balb/c mice, were confirmed to be viable as MRI 
contrast agents.  Later formulations were reported to show contrast enhancement of hepatic 
metastases in rats.97, 98 
A key advantage of liposomal nanoparticles is the tunable composition of the bilayer 
structure.  Amphiphiles with different unique properties can be used to tune the 
characteristics and behavior of the liposome.  In addition to the incorporation of Gd(III)-
based MR contrast agents in the liposome bilayer, they also allow for multimodal imaging by 
including contrast agents for optical imaging,99, 100 single-photon emission computed 
tomography (SPECT),101-103 and improved T2-weighted enhancement.104.  Another important 
potential of liposomes lies in the ability to add cell-targeting moieties to the bilayer surface.  
This is generally accomplished by synthesis of hydrophilic targeting molecules with 
hydrophilic tails to be incorporated into the bilayer as amphiphiles.  A number of target-
specific liposome-based contrast agents have already been explored for imaging IGROV-1 
xenograft tumors99 and hepatic metastases98 in rodents. 
 
1.2.4 Microemulsion-templated wax nanoparticles 
Oil-in-water microemulsions have been used as templates to engineer stable 
emulsifying wax nanoparticles containing gadolinium for potential use as MRI contrast 
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agents.105   Using a simple, reproducible technique (Figure 1.5) reported by Mumper et al. 
table wax nanoparticles of ~125 nm in diameter were produced.  This synthetic procedure is 
scalable to industrial production levels.106-108  The wax nanoparticles were first reported as 
delivery vessels of Gd(III) existing with a variety of hydrophobic ligands, such as 
acetylacetonate or hexanedione, for potential neutron capture therapy.   
To adapt for use as an MRI contrast agent precursor, dimyristoyl 
phosphoethanolamine diethylene triamine pentaacetate (DTPA) molecules were added during 
the nanoparticle formation.  Preloading the dimyristoyl phosphoethanolamine DTPA with 
Gd(III) before particle formation could greatly enhance the Gd(III) loading.  With recent 
safety concerns with Gd(III) toward patients prone to renal failure, limiting Gd(III) may be a 
beneficial strategy.  In addition, introduction of Gd(III) after nanoparticle formation would 
coordinate only surfaced exposed dimyristoyl phosphoethanolamine DTPA with ready access 
to water, maximizing the efficiency of each metal center to relax water protons.   
 
 
Figure 1.7 Schematic representation of the formation of “wax” nanoparticles by 
microemulsion template synthesis using variable temperature techniques. 
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The wax nanoparticles have a payload of approximately 105 Gd(III) per nanoparticle, 
determined through inductively coupled plasma-atomic emission spectroscopy.  In a 4.7T 
MR scanner, relaxivities were determined to be r1 = 7.1 and r2 = 13.0 per s-1 per mM Gd, 
suspended in 10% bovine serum.  Zn(II) and Cu(II) were used as competing ions for 
transmetallation kinetics of Gd(III) from the nanoparticles.  Kinetic constants of K1 = 0.033 
and K-1 = 0.022 h-1 with an equilibrium constant of 1.5  and thermodynamic binding constant 
for Gd(III) to the nanoparticles of  ~1018 M-1 were determined.  
Polyethylene glycol (PEG; average MW = 5000) was later incorporated into the 
Gd(III)-containing wax nanoparticles.109  The PEG molecules reduce the uptake by the RES 
system, allowing longer blood circulation times.  Using the enhanced permeability and 
retention (EPR) effect caused by the leaky vasculature of tumors, the PEGylated Gd(III)-
containing wax nanoparticles were used for MRI of nude mice bearing A549 lung carcinoma 
xenografts.  Detailed biodistribution profiles and pharmacokinetics reported in these animals, 
with tumor uptake of Gd(III) consistent with values of T1 enhancement from MRI.   
 
1.2.5 Hybrid silica nanoparticles 
Perfluorocarbon microemulsion, liposomal, and wax nanoparticles described above 
tend to be larger in size with diameters typically in 125-300 nm.  Such particles are useful for 
intravascular applications but might not efficiently pass through blood vessel for 
extravascular imaging.  The Lin group has sought to develop Gd-containing hybrid 
nanoparticles that have tunable sizes.  Highly robust hybrid multimodal contrast agents have 
been developed using silica nanoparticles of diameters from 20 to 100 nm.  Silica, a network 
of SiO2, is often used to develop functional materials by grafting alkylsiloxane-containing 
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agents.  In physiological systems, the material is inert and shows negligible acute toxicity in 
tissues and cells.  The preparation and industrial use of silica particles are well established.  
Ammonia catalyzed hydrolysis of tetraethylorthosilicate (the so called Stöber synthesis) is a 
well established route for the production of silica particles.110, 111    
Previously, the Lin group has designed hybrid silica nanoparticles with potential 
utility as multimodal imaging agents.112  Using a well-established water-in-oil reverse 
microemulsion synthetic procedure, nanoparticles with luminescent [Ru(bpy)3]Cl2 core and 
silylated Gd(III) complex surface coatings were prepared for optical and MR imaging.  In 
supplement to a monolayer system of Gd(III) chelate surface coating, a multilayer system 
was also developed for increased Gd(III) loading.  The nanomaterials were extensively 
characterized by TEM, TGA, DCP, and relaxivity measurements in a clinical MR scanner.   
The nanoparticles were further evaluated as multimodal imaging agents with in vitro 
studies using cell viability assays, confocal fluorescence microscopy, flow cytometry, and 
MRI of cell pellets.  The ability to label monocytes was specifically studied, because of these 
cells’ participation in mounting inflammatory responses and adherent phagocytic capacity.  
Further, the nanomaterials were shown to be robust and resist degradation by the phagocytic 
monocytes after intracellular uptake.  Thus, these hybrid nanomaterials were determined to 
be attractive for tracking labeled monocytes in in vivo disease models of inflammatory 
arthritis.  Chapter 2 describes the efficacy of the monolayer coated nanoparticle for early 
detection of collagen-induced arthritis in murine mouse models.   
In order to design further methods of increasing Gd(III) payloads on the surfaces of 
hybrid silica nanomaterials, our group devised a polyelectrolyte layer-by-layer self-assembly 
approach to increase the Gd(III) loading.113  Unlike the previously described multilayer 
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system of silylated Gd(III) complexes,112 this approach maintains water accessibility to the 
metal centers for efficient water proton relaxation.  MR-enhancing Gd(III)-chelate oligomers 
with a net positive charge were deposited onto the negatively charged surface of the 
aforementioned silica nanoparticles with a monolayer of Gd(III) complexes.  The addition of 
polyanion layers could be utilized for incorporating additional layers of Gd(III)-chelate 
oligomer.  The alternating, stepwise layer-by-layer deposition of polyanions and polycations 
produces flexible architectures of macromolecules on nanomaterial surfaces.  Further, 
electrostatics could be used to add cancer targeting peptides to the surface of the 
nanoparticles.  Chapter 3 describes the steps and characterization of these hybrid 
nanomaterials for increasing MR relaxivities and targeting of cancer cells.   
 
1.3 Hybrid nanomaterials for protein purification 
Recent advances in proteomics provide the ability to design and generate many 
recombinant proteins in cell cultures.  A large number of proteins can be produced in large 
quantities for research and pharmaceutical purposes.  The purification of proteins however 
remains a significant challenge due to the complexities of their isolation from the biological 
systems.  After the protein is produced, release is achieved through cell lysis, which can be 
accomplished through mechanical disruption, sonication, freeze/thaw, mortar/pestle grinding, 
detergents, or protease inhibitors.  The crude cell lysate mixtures from these processes 
contain cell debris and/or surfactants.  Many techniques have been employed to purify 
desired proteins, including precipitation, dialysis, gel filtration, ion exchange 
chromatography, and affinity chromatography. 
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Affinity chromatography uses specific binding interactions between molecules to 
purify target proteins.  A variety of ligands, ranging from antibodies, proteins (avidin) and 
protein fragments (Protein A or G), peptides (glutathione), carbohydrates (dextrin), and small 
molecules (biotin), are available for interaction with the target protein.  The ligand of choice 
may be immobilized onto a solid support to bind the target, allowing impurities to be washed 
away, before elution of purified protein.  Immobilized metal affinity chromatography 
(IMAC)114 uses chelated metal ions to biding and purify recombinant fusion proteins. 
For IMAC, the desired recombinant protein is designed to include a tag of six or more 
histidines at the N- or C-terminus (His×6 tag).  Histidine contains an imidazole moiety that is 
able to bind metal ions.  To isolate the target protein, the crude cell lysate is passed through 
resin containing immobilized metal ions.  Nickel(II) ions chelated by an organic molecule 
with three or four binding sites, such as nitrilotriacetic acid (NTA), is a commonly used for 
resin immobilization.115 The histidine tag will bind with the chelated metal with greater 
affinity than untagged impurities.  After thorough washing, an imidazole solution is used to 
release the purified protein from the chelated metal ions.   
The resin used in IMAC is a key parameter for the purification of the protein, as the 
affinity support needs to be chemically modifiable for attachment of protein-binding metal 
ions and have a high surface area for interaction.  Porous gel supports, such as cross-linked 
agarose or polyacrylamide are widely used, but easily crush under pressure and often 
necessitate the use of gravity flow columns.  Microscale magnetic beads are a convenient 
support for affinity chromatography.  The beads can be quickly immobilized with a magnet, 
allowing facile manipulation of supernatant washes and elutions.  Magnetic nanoparticles 
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(~10 nm), which are several orders of magnitude smaller than commercially-available 
magnetic beads (~50 μm), have obvious surface area-to-volume advantages. 
Bing Xu and coworkers have shown use of dopamine to design as a robust 
bifunctional molecule able to anchor chelated nickel(II) ions onto an the iron oxide surface of 
a cobalt nanoparticle.116, 117  Dopamine contains a catechol moiety, a bidentate enediol, that is 
capable of tightly coordinating to transition metal ions.  The interaction between the catechol 
moiety of dopamine and the iron on the surface of the nanoparticle was shown to be stable at 
high salt concentrations, in the presence of detergents, and in boiling water.  These materials 
could be used to purify highly overexpressed green fluorescent protein (GFP) from E. coli 
cell lysates.   
Significant effort has been devoted to gaining better understanding of the interaction 
between Ni-NTA/His×6 tag to improve the IMAC protein purification process.  Using 
fluorescence anisotropy and fluorescence resonance energy transfer, Ebright et al. 
demonstrated the enhanced binding of the His×6 tag to a bivalent Ni-NTA compared to 
monovalent Ni-NTA.118  Piehler et al. has continued to examine further affinity 
enhancements by multivalency of Ni-NTA to His×6 tag.119, 120 Combining the strong affinity 
of multivalent Ni-NTA molecules with the increased surface area of superparamagnetic 
nanoparticles will allow improvement of IMAC protein purification. 
The Lin group has designed a new bivalent Ni-NTA molecule with the catechol 
anchor for binding to iron oxide nanoparticles to create a hybrid system for protein 
purification.121  The study showed that the multivalency effect led to enhanced binding of 
His×6 tagged proteins in native, folded conformations.  Recombinant proteins often must be 
denatured during the IMAC purification process to expose the full His×6 tag from the protein 
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structure to ensure effective binding.  Denaturing proteins can increase the efficiency of 
purification, but may not yield an active product.  Refolding proteins in the test tube cannot 
accurately mimic the folding conditions within the cell during translation.  A large 
percentage of recombinant proteins remain difficult to purify, hindering research on many 
important proteins.122   
This work demonstrates the utility of the multivalency strategy in enhancing the 
binding of His×6-tagged proteins in their native, folded conformations.  Selective 
purification of His×6-tagged proteins from crude cell lysates was achieved by using the 
Ni(II)-loaded iron oxide nanoparticles.  The present platform is capable of efficient 
purification of His×6-tagged proteins that are expressed at low levels in mammalian cells.  
The present hybrid nanomaterial represents a novel nanoparticle-based high-capacity protein 
purification system with shorter incubation times, proportionally large washes, and 
significantly smaller elution volumes compared to commercially available microbeads.   
 
1.4  Concluding remarks 
We have introduced in this chapter several hybrid nanomaterial systems and their 
applications in biological applications such as MR image diagnostics and protein 
purification.  In each case, the hybrid material system outperformed the current technology as 
a result of the unique combination of interesting properties.  The success in these areas of 
research provides a testament to organic/inorganic hybrid nanomaterials’s ability to offer 
many interesting characteristics that do not exist in either inorganic nanostructures or 
polymer colloidal particles alone.  The modular synthetic procedures for organic/inorganic 
hybrid nanomaterials should allow further fine-tuning of their properties for target 
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applications.  Such an amalgam of molecular chemistry and nanotechnology promises to lead 
to new hybrid nanomaterials for a wide range of biomedical applications, such as imaging or 
protein purification, across multiple scientific fields.   
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CHAPTER 2 
 
 
MULTIMODAL NANOPARTICLE CONTRAST AGENTS FOR TARGETED 
MONOCYTE IMAGING OF SYNOVIAL INFILTRATION IN INFLAMMATORY 
ARTHRITIS DISEASE MODELS 
 
 
2.1  Introduction 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease 
characterized by progressive damage of joints.  Affecting 1-2% of the worldwide population, 
disease onset can occur at any age of adulthood (25-50), and has a three times greater 
incidence in women.1 As one of the most common immune-mediated inflammatory disease, 
the aberrant immune system causes swelling, pain, and stiffness of the joint as well as 
destruction and deformity of the cartilage, bone, and ligaments. Thus, RA results in 
diminished quality of life and has been linked to increased risk of myocardial infarction, 
lymphoma, osteoporosis, and reduction of life expectancy.2-4  Events that initiate disease are 
unclear, though the presence and activation of T-cells, B-cells, and macrophages in the 
inflamed joint is generally accepted.  While a cure does not exist, the early treatment of RA 
using existing disease modifying and anti-inflammatory therapies (i.e. Rituxan®, Enbrel®, 
Humira®) can prevent irreversible joint damage, a primary cause of the associated chronic 
pain. 
 Diagnosis of RA is largely dependent on clinical criteria established by the American 
Rheumatism Association in 1987.  Four symptoms must be present for at least six weeks: 
early morning joint stiffness; polyarticular inflammation; swelling of proximal 
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interphalangeal, metacarpophalangeal, or wrist joints; and symmetric swelling.5  Serologic 
tests, such as measurement of rheumatoid factor (RF) and anti-cyclic citrullinated peptides, 
can also be used to help confirm diagnosis but cannot act as stand-alone assays.  
Seronegative RF appears in approximately 20% of RA patients and can also be positive in 
other diseases.6  For the research and treatment of RA, the ability to noninvasively 
characterize early inflammatory events within the joints remains a significant challenge.   
 
 
Figure 2.1 Diagram of normal joint compared to inflamed joint found in rheumatoid arthritis.  
(Adapted from reference 7.) 
      
Conventional radiography (CR or X-ray) remains the standard diagnostic, but 
ultrasound, computed tomography (CT), and MRI are gaining popularity.8 X-rays pass 
through soft tissues but are absorbed or scattered by denser bones, providing high quality 
images of bony structure.  In 2005, a long term comparison study of individual imaging 
modalities for rheumatoid arthritis was published, establishing the superiority of MRI over 
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CR.9  In this study, bone erosions could be detected 7 years sooner by MRI compared to CR.  
Inherently dependent on water distribution, MRI allows detection of early soft tissue 
changes, such as tissue inflammation, edema formation, and cartilage damage.10-14  These 
soft tissue changes occur earlier in disease progression than bone erosions, thus provide a 
more effective measure of response to treatment.15, 16   
 
A.  B.  
Figure 2.2 Hands of rheumatoid arthritis patient imaged A) visually and B) conventional 
radiography (X-Ray) showing bone damage detail but little soft tissue information.17 
 
While much more sensitive, MRI is often limited to structural anatomy that lack 
mechanistic information of disease.  Because cellular and molecular events long precede 
anatomic derangement, detection beyond the scope of conventional MRI is required to 
recognize disease earlier in order to design more targeted biologic therapies.  The synovium, 
a thin membrane that provides lubrication and nourishment to the joint, is a focus of 
inflammatory activity and rheumatoid arthritis.  Contrast-enhanced MRI can be used to 
improve contrast in synovial tissues for delineation from tendon sheaths, cartilage, and 
effusion.18  Low molecular weight metal-chelate contrast agents, such as Magnevist®, 
Omniscan®, or Dotarem®, have been used to enhance signal in interstitial fluid resulting 
from increased endothelial tissue permeability and blood flow caused by inflammatory 
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arthritis.19  Specificity of these small Gd(III) contrast agents has some limited utility, though 
signal enhancement is often seen in both normal and inflammatory tissues.  Using dynamic 
contrast-enhanced MRI, a modification of traditional techniques to help correlate the 
pathophysiology of synovial inflammation and response to treatment, acquisition of many 
sequential images immediately after administration of the contrast agent becomes possible 
and allows the analysis of synovial perfusion and capillary permeability.16  While being able 
to give vascular detail of disease, the low molecular weight Gd(III)-chelate contrast agents 
are limited by their quick clearance from the blood and inability to sensitively label cellular 
and molecular markers for inflammation. 
 Molecular markers such as αvβ3 integrins are expressed on synovial blood vessels in 
RA20, 21 and regulate migration and proliferation of endothelial cells in the synovial tissue.  
Targeted induction of apoptosis in the synovial neovasculature has been demonstrated as a 
potent therapy for RA.22  Using RGD peptides for integrin binding,23, 24 murine collagen-
induced arthritis can be suppressed by targeted apoptosis in cells of synovial 
neovasculature.25  Integrin targeting is an example of a molecular marker that is desirable for 
use in diagnosis of neoangiogenesis seen in RA as well as other diseases.  Unfortunately, 
currently available low molecular weight Gd(III)-chelates require concentrations orders of 
magnitude higher than available on overexpressed biomarkers on disease cell surfaces.26  A 
potential solution for this concentration gap is the development of nanomaterials with higher 
MR sensitivity. 
As MRI contrast nanomaterials with higher sensitivity are generated and optimized 
for targeted imaging, rapid uptake by the reticuloendothelial system (RES) is a major 
concern.  Phagocytic cells, residing in the lymph nodes, spleen, and liver, clean blood by 
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uptake of particulate matter.  This process is very fast, and often significantly interferes with 
targeted nanomaterials.  Yet, these phagocytic cells also play an important role in the 
immune response, inflammation, and thus RA.  Labeling phagocytic cells of the RES using 
inherent phagocytic activity toward particulate matter (i.e., contrast-enhancing nanoparticles) 
is an attractive alternative to helping image immunological responses in RA and subsequent 
soft tissue changes.   
Recently, particular interest has surrounded monocytes and synovial macrophages as 
important mediators of tissue and bony destruction in inflammatory arthritis.27-29  Activated 
macrophages are thought to play an important role in RA, and the total number of residing 
synovial macrophages correlates with RA disease activity (Figure 2.3).30, 31  Generally a 
membrane of one to two layers, the synovium thickens due to infiltration by blood 
monocytes.  The damage caused by these cells eventually cause irreversible destruction of 
the cartilage and bone.  Particulate contrast agents, such as ultrasmall superparamagnetic iron 
oxide (USPIO), has been used in investigational studies in inflammatory disease responses as 
labels of hematopoetic phagocytic cells.29, 32-34  USPIO are internalized by a variety of cells, 
but preferentially label monocytes/macrophages.  In the collagen-induced arthritis (CIA)34 
and in the experimental antigen induced arthritis29, 31 rodent models, USPIO particles showed 
a negative (dampened) signal intensity on MR images comparing arthritic to normal mouse 
joints.  These studies support the feasibility of cellular tracking in vivo and suggest their 
potential application for monitoring inflammatory events and response to therapy.  As 
cellular immunotherapies emerge,35-37 where cells are used as therapeutic delivery vehicles, 
non-invasive cell in vivo imaging techniques are needed to monitor these therapies and track 
the fate of the administered cells.38   
40 
 
A)   B)  
C)  D)  
Figure 2.3 Hematoxylin and eosin (H&E) stains of histological stains of A) normal rat knee 
joint at 10X magnification, B) normal rat knee joint at 100X magnification, C) arthritic rat 
knee joint at 10X magnification, and D) arthritic rat knee joint at 100X magnification.  Black 
arrows indicate the synovium, and hematoxylin stained cells (purple) show the infiltrating 
basophilic leukocytes.31  
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Our group has produced a new multimodal nanoparticle (MNP) contrast agent 
capable of T1- and T2- enhancement as well boasting relatively long fluorescence emission 
wavelengths39.  MNP outperforms both Gd-DTPA and USPIO in T1-enhancement and is 
comparable to USPIO in T2-enhancement.  This contrast agent has been shown to efficiently 
label monocytes for MRI and fluorescence without detriment to cell viability.  It is our 
hypothesis that MNP contrast agents can eventually be used to noninvasively measure and 
guide treatment in inflammatory arthritis.  Specifically, we will image animal models of 
inflammatory arthritis using multiple modalities to improve current MR imaging 
technologies (Figure 2.4).  This transformational research aims to help develop advances to 
guide RA therapies and generate knowledge that cannot be obtained by our current methods 
of analysis.   
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2.2 Results and Discussion 
2.2.1 Description of the multimodal nanoparticle (MNP) contrast agent 
The multimodal nanoparticle contrast agent used in these studies is composed of a 
Ru(bpy)3Cl2 dye-doped silica nanoparticle with paramagnetic coating of a gadolinium(III)-
diethylene triamine tetraacetic acid (DTTA)-silane (Figure 2.5).  The Gd(III) chelate is 
structurally similar to the clinically used low molecular weight contrast agent Gd-DTPA.  
One of the acetate groups is replaced with a silane moiety for immobilization onto the 
surface of the silica nanoparticle.  Thus, two water molecules can coordinate simultaneously 
to the paramagnetic metal center compared to the one water molecule that coordinates to Gd-
DTPA potentially increasing proton relaxation efficiency.  Gd(III) remains tightly bound to 
the chelator despite the loss of a coordinating acetate; loss of Gd(III) may result in increased 
toxicity due to interference with Ca(II) signaling.   
The nanoparticles have a spherical morphology and are highly monodisperse with a 
37 nm mean diameter.  Characterization was performed by scanning electron microscopy 
(SEM), transmission electron microscopy (TEM), thermogravimetric analysis (TGA), and 
direct current plasma (DCP) elemental analysis.  In a clinical 3.0 Tesla MR imaging scanner, 
the r1 and r2 were measured to be 2.0 x 105 and 6.1 x 105 s-1, respectively.  MNP has been 
validated for in vitro uptake by murine monocytes, demonstrating fluorescence and MR 
enhancement.34 
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Figure 2.5 Schematic representation of the multimodal nanoparticle (MNP) contrast agent 
with luminescent Ru(bpy)3Cl2-doped core and Gd(DTTA) surface immobilized. 
 
 
2.2.2 Monocytes and their role in inflammation 
 Monocytes are leukocytes that circulate in the bloodstream and can actively 
participate in immune responses toward pathogens.  The main function of this type of cell is 
to mature into either macrophages for phagocytosis and digestion of undesirable material or 
to present antigens and trigger immune responses.  Monocytes are produced from 
hematopoetic stem cells (hemocytoblasts) found in the bone marrow.  The multipotency of 
these hemocytoblasts gives rise to a range of blood cell types: myeloid, lymphoid, and new 
stem cells.  Monocytes are derived from myeloid origin, as hemocytoblasts first commit to 
the myeloid progenitor state, before becoming myeloblasts, and then monocytes.  
Approximately 400 million monocytes exist per liter of human blood, carefully guarding 
against infection. 
Macrophages are monocytes that have left the bloodstream and have migrated into 
tissue actively undergoing inflammation.  Foreign material is removed from the tissue by 
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endocytosis, specifically phagocytosis.  During this process, macrophages can engulf 
particulate matter using its cell membrane to form an endosome, which can fuse with a 
lysosome to introduce superoxide (O2-), hypochlorite (HOCl), and enzymes.  These harsh 
conditions are suitable for breakdown of undesirable material, such as pathogenic 
microorganism or sensescent/dead/damaged cells. 
Acute and chronic inflammation is an immune response that monocytes and their 
derivative macrophages are major participants.  Inflammation is an essential healing process 
invoked by an organism toward tissue infection or damage.  Monocytes respond to cellular 
signals, such as selectins or chemokines, to migrate from the bloodstream into the damaged 
tissue.  Acting as macrophages within tissue, foreign debris is cleared and degraded to allow 
for regeneration of healthy tissue.  While vital to the survival of the organism, this process 
can go awry resulting in autoimmune diseases such as RA.   
In RA, monocytes have been implicated as a key contributor to dysfunctional immune 
response, specifically to joint tissue.  Monocytes are known to infiltrate the synovial tissue 
during the unwanted inflammatory response.33  Joints damage initially inflicted on the 
synovium eventually causes destruction to the cartilage and bone.   Monocytes can become 
activated by endotoxins derived from pathogens40 to release inflammatory mediators: tumor 
necrosis factor alpha (TNF-α)41-43 and interleukins (IL) -1 and -6.44  Upon activation, higher 
phagocytosis levels of particulate matter has also been demonstrated.45  Since these immune 
cells play a critical role in regulating the inflammatory response, methods of tracking for 
studying is highly desirable.   
The inherent phagocytic activities of live monocytes can act as a major hurdle for 
conventional labeling techniques.  Common cell surface labeling techniques, such as 
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fluorescent antibodies, will be engulfed and digested.  Also, antibodies labeled with Gd-
DTPA generally do not have sufficient sensitivity for in vivo studies of pathogenesis.  
Instead, particulate uptake was used for labeling and tracking monocytes in vitro and in vivo.  
We found that murine monocytes could quickly uptake particulate aggregates of iron oxide 
nanoparticles (Figure 2.6).   In this experiment, phagocytosis of large visible aggregates 
occurred within 45 minutes, with evidence of small vesicle formation for uptake of particles 
not visible by light microscopy at 100X magnification.  Cells appeared viable by trypan blue 
examination up to approximately 2 weeks after uptake of iron oxide particulates.  These 
observations were supported by literature reports of uptake of iron oxide by human 
monocytes.46  
We hypothesized that monocytes could efficiently uptake MNP, by utilizing their 
inherent phagocytic activity, for labeling and tracking cell pathogenesis in disease models.  
Using the luminescent properties of MNP, we characterized monocytes movement using in 
vitro assays, histopathology, and in vivo optical imaging of low tissue depth joints.  MR 
modalities were used to achieve further in vivo imaging of intricate joint structure and 
achieve greater resolution than what is available through optical imaging.   
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Figure 2.6 Monocytes can quickly engulf particulate matter (large aggregates of iron oxide 
nanoparticles) shown in these live cell bright field microscope images at 20X magnification.   
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2.2.3 The need for a robust system to track monocytes 
 As noted in the previous section, phagocytic cells, such as monocytes, have a primary 
function of digesting foreign material.  In order to effectively track the action of monocytes 
in an active inflammatory process, we realized the need for a robust system able to withstand 
the harsh conditions of the endosome.  Silica is known to be robust and biocompatible, 
having been used for industrial catalysis47-50 but have also been used for cellular studies.51-54  
With reports of doping silica nanoparticles with fluorescent molecules,55-57 we believed that 
coating luminescent silica nanoparticles with chelated metal centers could provide a robust 
contrast agent capable of withstanding harsh endosomal conditions.  We found the resulting 
material, MNP, could be label monocytes without diminishing their viability to track 
monocytes movement within a disease model.  MNP was monitored for over 4 weeks and 
found stable in vitro and in vivo.   
 
2.2.4 Fluorescence confocal microscopy of labeled monocytes 
 To label monocytes in vitro, cells were incubated with MNP to allow for phagocytic 
uptake.  Since MNP does not form large aggregates visible by light microscopy, confocal 
fluorescence was used to visualize nanoparticle uptake.  Confocal laser scanning microscopy 
is a valuable in vitro imaging technique that has been used extensively to examine biological 
samples.  Microscopy principles are similar to traditional fluorescence microscopy with the 
use of objective lens and a series of excitation/emission filters, but with a few key 
differences.  Particularly, resolution in confocal microscopy is greatly enhanced over 
conventional fluorescence microscopy because an aperture or pinhole is used to block out-of-
focus light.  The result is sharper images from luminescence arriving directly from the focal 
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point of luminescence.  Light can be detected at various z-axis planes, allowing visualization 
of a particular “slice” of a sample.  Additionally, the “slices” can be stacked, generating 
three-dimensional composite images by software.   
Imaging at z-axis planes is especially important for imaging monocytes with MNP 
uptake.  While the 37 nm diameter MNP cannot be seen by confocal laser scanning 
microscopy (neither bright field nor fluorescence), the accumulation of MNP within the cells 
was apparent (Figure 2.7).  By detecting fluorescence of a z-slice that cuts through the 
centers of the monocytes, MNP fluorescence within the cells was detected.  Focal regions of 
fluorescence indicate concentration of the nanoparticles into endosomal vacuoles.  Ring 
patterned fluorescence was not seen, which would be indicative of surface labeling of cells.  
Inspection of the representative images of MNP-labeled monocytes populations show high 
labeling efficiency that is also confirmed by flow cytometry. 
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A.  
B.  
Figure 2.7  Laser scanning confocal  microscopy images of murine monocytes incubated 
with MNP at 63X magnification under A) bright field and B) 433 nm excitation with 500-
550 nm emission settings.   
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2.2.5 In vitro MRI of MNP labeled monocytes 
 To evaluate potential use for in vivo applications for tracking monocytes using MR-
enhancing modalities of MNP, in vitro MRI was performed on labeled monocytes.  After 
incubating monocytes with MNP, the cells are washed and pelleted into Eppendorf tubes 
before being placed in a 3.0T MR scanner.  Figure 2.8 demonstrates contrast enhancement in 
T1- and T2-weighted MR imaging when compared to unlabeled cells.  T1-weighted images 
show a significant signal enhancement, while T2-weighted images show signal void of MNP-
labeled cells.  Both modalities may be useful in imaging disease and provide information 
regarding cellular pathogenesis.   
 
A.  B.  
Figure 2.8 In vitro MR images of murine monocytes unlabeled (left) and MNP-labeled (right) 
showing clear contrast signal contrast enhancement in A) T1-weighted and B) T2-weighted 
modalities. 
 
2.2.6 Flow cytometry of MNP labeled monocytes 
 Microfluidic advances have led to the development of the modern flow cytometer 
extensively used by immunologists and other scientists for studying populations of cells and 
microscale structures.  A major technological challenge was the accurate measurement of 
single particle events as they pass through a detector.  Typical manufacturing processes could 
not create microfluidic feature sizes that could effectively force particles to move 
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individually through channels.  Hydrodynamic focusing using sheath fluid to surround 
particulate-containing fluid within a larger, manufactured tube was found ideal for narrowing 
the sample stream.  Fluid dynamics allow two fluids that differ in velocity and density to 
resist mixing, enabling a stable two-layer flow, and thus producing the necessary stream 
diameter for single event detection. 
 Detectors for light scattering or fluorescence can be very useful for probing cellular 
samples in flow cytometry.  Forward scattered (FS) light is measured through the sample 
stream, while side scattered (SS) light is measured orthogonal to the sample stream.  Such 
scattered light is useful for measurements of cellular populations, as information about size 
and granularity of cells is generated.  Larger cells result in higher FS signals than smaller 
cells.  Cells of greater complexity, such as those with more granules or organelles, create 
higher amounts of SS light.  Fluorescence, like SS light, is also measured by detectors 
perpendicular to the sample stream.  In immunological assays, a wide range of fluorescently-
tagged antibodies specific for cellular markers are extensively used for studying populations.  
This technique is much more powerful and absolute in counting and sorting populations than 
light scattering detection.  Cells can be probed and sorted for functional characteristics 
labeled by fluorescent affinity molecules in conjunction to morphological characteristics 
provided by light scattering.   
 We used flow cytometry to measure the uptake efficiency of MNP by murine 
monocytes (Figure 2.9).  Cells that were and were not incubated with MNP were probed in a 
flow cytometer using light scattering and fluorescence.  A plot of SS versus FS light was 
used to determine healthy cells used for fluorescent measurement.  The light scattering data 
of the inset in Figure 2.9 shows “R2” as the region of interest encompassing the large 
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majority of cellular events, while those outside of the ellipse consist of dead cells and debris.  
Monocytes incubated with and without MNP had similar levels of events outside of the 
region of interest, indicating that the dead cells and debris are a result of the normal cell cycle 
rather than toxicity induced by MNP.  Finally, fluorescence was used to count over 1x105 
MNP-labeled (blue curve) and unlabeled cells (red curve).  Increasing concentrations of 
MNP used for incubating with monocytes were proportional to labeling efficiency.  
Presumably, the cells had an upper limit to MNP-labeling dependant on uptake capacity.  
Monocytes could be labeled in over 98% efficiency determined by increase in fluorescence 
intensity with little toxicity to cells.  This corresponds with the qualitative level of labeling 
seen in confocal fluorescence imaging.   
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Figure 2.9  Flow cytometry analysis murine monocytes labeled with different MNP 
concentrations; plotted as cell counts (y-axis) versus luminescence intensity (x-axis).  Insets 
show light scattering data to determine healthy cells sampled and counted in region of 
interest: R1, R2.  of MNP labeled showing increased fluorescence intensity of labeled (blue 
curve) cells compared to unlabeled (red curve) cells.  (a) 0 mg MNP per 1×106 cells in 2 mL 
media; R1 = 95.5% of total events; (b) 0.004 mg  MNP per 1×106 in 2 mL media; 0.6% NP 
labeling efficiency, R2 =94.0% of total; (c) 0.042 mg MNP per 1×106 in 2 mL media; 10.8% 
NP labeling efficiency, R2 = 94.2% of total events; (d) 0.418 mg MNP per 1×106 in 2 mL 
media; 98.0% NP labeling efficiency, R2 = 90.9% of total events; (e) 2.140 mg MNP per 
1×106 in 2 mL media; 99.4% NP labeling efficiency, R2 = 91.3% of total events. 
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2.2.7 Cell viability of monocytes incubated with MNP 
 MNP toxicity was measured using a commercially available colorimetric assay 
measuring enzymatic activity of the cells.  (3-4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium salt (MTS) is converted by cells 
to the derivative water-soluble formazan product that absorbs at 490 nm.  Literature has 
reported MTS assay for measurement of cell viability and proliferation; formazan generation 
is time-dependent and proportional to the number of viable cells.58, 59 
 
 
Figure 2.10 Structures of substrate and product used to measure cell viability of cells. 
 
Upon incubation of murine monocytes with various concentrations of MNP, MTS 
assay showed monocytes are fully viable even at high concentrations of nanoparticle.  
Monocytes were incubated with MNP concentrations from 0.0123 μg up to 123 μg per 5000 
cells in 120 μL media for 22 hours, and were found to be able to convert MTS as effectively 
as normal cells.  This result indicates that the nanomaterial construct is not toxic to 
monocytes, which is expected because components are also known to have little toxicity.   
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Thus, nanoparticle labeling may be a useful method to track monocytes, as uptake of MNP 
does not seem to hinder viability or proliferation.   
 
 
 
Figure 2.11 MTS assay results of murine monocytes incubated with 0, 0.0123, 0.123, 1.23, 
12.3, and 123 μg MNP per 5000 cells showing no toxicity and high cell viability. 
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2.2.8 Determining background fluorescence in non-arthritic joints of control animals 
injected with and without MNP 
At 12 hour time points following intravenous injection of MNP contrast agent, optical 
imaging was performed for fluorescence detection.  Figure 2.12 shows superimposed images 
of animals in both photographic (white light) and fluorescence (DsRed emission filter) 
channels.  Control animals, vehicle-immunized without heterologous bovine collagen, are 
used to establish baseline fluorescence emission for animals injected with saline (or 0 mg 
MNP / kg animal), 125 mg MNP / kg animal, and 250 mg MNP / kg animal.  These control 
animals injected with variable MNP dose demonstrate a slight increase in fluorescence 
background of the paws as MNP dose was increased.  This small increase in fluorescence 
signal is presumably due to the vascular trapping of nanoparticle within the paw circulation.   
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Figure 2.12 In vivo optical images of normal animals injected with A) saline, B) 125 mg/kg 
MNP, or C) 250 mg/kg MNP and collagen-induced arthritis (CIA) animals injected with D) 
saline, E) 125 mg/kg MNP, or F) 250 mg/kg MNP.  Luminescence intensity in MNP-treated 
arthritic paws had strong positive correlation with the assigned clinical index score in 
animals that received either H) 125 mg MNP/kg (r = 0.82, p = 0.01) or I) 250 mg MNP/kg (r 
= 0.89, p = 0.002). Arthritis was not symmetric and varies for each animal.   
 
 
r  = 0.76, p = 0.0683                 r = 0.82, p = 0.0128               r = 0.89, p = 0.0017 
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2.2.9 Determining background fluorescence in arthritic joints of control animals 
injected with and without MNP 
As compared to the non-arthritic group, animals with arthritis showed a dramatic 
increase in paw fluorescence.  Arthritic animals given higher doses responded with greater 
paw fluorescence.  The arthritic mouse injected with saline, shown in Figure 1, demonstrates 
little increase in fluorescence measured from the left hindlimb without arthritis (evaluated 
based on paw swelling) when compared to the right hindlimb with arthritis.  This increase in 
fluorescence is due to the paw swelling of the arthritic hindlimb, which results in a greater 
amount of surface area from which tissue autofluorescence was generated.  In the 125 mg / 
kg dosed arthritic animal shown, the left hindlimb (non-arthritic) clearly shows less 
fluorescence than the arthritic right hindlimb.  The fluorescence of the arthritic right hindlimb 
is also significantly enhanced in contrast to the right arthritic hindlimb of arthritic animal 
dosed with saline (0 mg / kg).  The fluorescence was further enhanced in the case of the 
arthritic animal dosed at 250 mg / kg.   
 
2.2.10 Correlation of optical imaging and magnetic resonance imaging in arthritic paws 
 Using the MR-enhancing modality of MNP, animals with inflamed joints were 
imaged using a 9.4T small animal scanner.  Animals were scanned before and 12 hours after 
125 mg / kg MNP administration.  The post-contrast image demonstrates a clear signal void 
compared to the pre-contrast image in the inflamed joints.  Enhanced T2 relaxation as a result 
of MNP deposition in the inflamed tissue causes the signal void and correlates appropriately 
with the post-contrast in vivo fluorescent enhancement.  The fluorescence images show a 
30% enhancement of fluorescence in the circled toe ROIs. 
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2.2.11 Magnetic resonance imaging: Relaxation time (T1, T2) mapping 
T1 and T2 relaxation time mapping is an MR imaging technique that has been found 
to quickly detect cartilage changes and provide quantifiable data in healthy children, 
adolescents, and adults as well as patients with juvenile rheumatoid arthritis (JRA).60-63   T1 
mapping with delayed administration of Gd-DTPA contrast agent has been shown to 
demonstrate loss of proteoglycan density in cartilage 63-65, but T1 and T2 mapping has yet to 
show changes as a result of cellular response.  Our studies indicate an increased sensitivity by 
T2 mapping MR imaging as compared to high resolution three-dimensional MR image.   
Figure 2.13 compares arthritic animals with early arthritis (day 30) and late arthritis 
(day 50), pre- and post-injection of MNP.  In early disease, the hind paws showed obvious 
enhancement of T2 relaxation time, but little to no change in T1 relaxation time.  Unlike low 
molecular weight Gd(III) contrast agents, MNP has significant T1- and T2- effects.  Often, 
parameters can be adjusted to weigh the effect in favor of T1 or T2.  In high concentrations, 
T2-effects dominate, outweighing T1-effects from being apparent even with parameter 
modification.  In this animal, there was no obvious detectable change in the high resolution 
MR image, but the T2 mapping image shows a marked enhancement of T2 relaxation, 
demonstrating the promise of relaxation time mapping for sensitive early detection of 
disease. 
Late arthritis did not detect significant T1- or T2-effects from MNP injection.  
Although this animal had heavy edema as result of inflammation, very little enhancement of 
T2 relaxation time was shown.  This is attributed to the lack of monocyte migration to the 
inflammation site.  At late stage arthritis, the inflamed site may be saturated with monocytes 
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that had migrated earlier, such as in the day 30 results, preventing significant new infiltration.  
Additionally, these results potentially support the idea that monocytes trafficking, rather than 
vascular trapping of MNP causes MNP deposition in the synovial joints.  An alternate mode 
of deposition may be the uptake of MNP by monocytes that have already infiltrated the joint, 
which indicate that monocytes in late stage arthritis may be less active.  Both modes of MNP 
deposition working in concert is possible, though difficult to clearly prove. 
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Figure 2.13 Representative T1 and T2 maps of arthritic animal hindlimbs showing pre- (day 
35) and post-MNP (day 36) contrast injection in a mouse with active inflammation.  The 
post-MNP contrast images were obtained 12 hours after injection with 2 separate doses of 
125 MNP/kg.  Changes in relaxation time are distinctly detected in T2 maps after MNP 
injection. 
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2.2.12 High-resolution Magnetic resonance imaging 
High-resolution MR images of collagen induced arthritis animals were scanned to 
show detailed anatomical structures not seen in T1- and T2- relaxation time maps and optical 
imaging.  These results are representative scans that clinicians may commonly see when 
examining human patients.  In Figure 2.14, an animal with arthritis is scanned by both high-
resolution MR and optical imaging.  The right hind paw of the animal post-injection of MNP 
shows luminescence enhancement when compared to the pre-injection optical image.  This is 
represented by the elliptical ROIs showing an increase from 2.1 X 106 to 3.4 X 106 
luminescent counts.  This corresponded well to the MRI scans, showing signal void in the 
toes of the animal as a result of T2-effects of MNP.  Slight signal void of toes in the left hind 
paw are also seen, which corresponds to the optical results.  MR and optical cannot be 
directly correlated because of positioning factors.  While MR can image slices of an 
anatomic structure, optical imaging will only provide data of the whole structure.  In this 
sense, optical imaging is severely limited because of the dependency on excitation and 
emission light penetration into the tissue.  For example, MNP accumulation closer to the skin 
surface will give greater luminescence than MNP accumulated further into the tissue.  Also, 
positioning of the limb can also greatly affect the measurement of luminescence.  Yet, optical 
imaging is an attractive potential diagnostic because it is inexpensive and less time 
consuming than MRI.   
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Figure 2.14 High resolution MRI and optical images of hind paws of collagen induced 
arthritis animals pre- and post- MNP injection.  Right hind paw shows higher fluorescence 
intensity and T2-effect signal void after MNP injection. 
 
2.2.13 Confocal fluorescence microscopy of arthritic joints 
 Tissue sections of arthritic hind paws were examined under light and confocal 
fluorescence microscopy.  The characteristic fluorescence of Ru(bpy)3Cl2 retained in the 
MNP core was specifically found in the synovial tissue where active inflammatory disease 
was present.  The nanoparticle contrast agent is hypothesized to in vivo label monocytes 
through phagocytosis.  As previously demonstrated, monocytes phagocytically loaded with 
MNP have been shown to be completely viable by MTS assay, potentially allowing activated 
cells to migrate and infiltrate joints during inflammation.  Figure 2.15 shows MNP 
fluorescence specifically in the “crescent” shaped synovium surrounding the calcaneus (heel 
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bone) of the ankle joint at 10X magnification.  Though a majority of MNP was localized in 
the synovial tissue surrounding the joint, some nanoparticle deposition was detected in the 
bone.  This may be evidence of monocytes infiltrating the bony structure and causing 
permanent damage.  Arthritic joints have apparent MNP deposition as measured by 
fluorescence, further magnification and immunofluorescence was necessary to examine 
cellular uptake and deposition.   
 
 
Figure 2.15 Overlay of 10X light and fluorescence images from hindlimbs of collagen-
induced arthritis animals showed MNP localizes in the synovial tissue (indicated by black 
triangles). 
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2.2.14 Immunofluorescence of arthritic joints 
Joint tissue slices stained for immune cells show that monocytes traffic nanoparticle 
to sites of inflammation under confocal fluorescence microscopy at 63X magnification.  
MNP contrast excites at 488 nm and emits at a 610 nm maximum wavelength, creating an 
ideal tandem stain with FITC-labeled antibodies.  Monocytes, B-cells, and T-cells are all 
known to take active roles in the immune response, but also all are known to infiltrate 
synovial tissue in RA.  As expected, monocytes, B-cells, and T-cells were present in the 
synovial tissue of the CIA mice, as shown by FITC fluorescence due to antibody stain.  Only 
monocytes stained with the monocyte/macrophage marker MOMA2-FITC have overlapping 
fluorescence with the MNP, showed intracellular monocyte uptake.  When stained with the 
T-cell marker anti-CD3-FITC, joint slices show little overlap with MNP fluorescence, due to 
low uptake by T-cells.  B-cells stained with anti-B220-FITC within the joints show a 
similarly low overlap with MNP fluorescence, indicative of little to no uptake by B-cells 
present in the inflamed tissue.  Overlap was indicated by the merging of fluorescence 
channels: FITC (green) + MNP (red) = overlay (yellow).  The relevance of these results is the 
demonstration of monocytes or macrophages with specific MNP uptake.  Although T-cells 
and B-cells also known to be present in sites of inflammation, they did not have nearly the 
same extent of MNP uptake. 
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Figure 2.16 Immunofluorescence microscope images of cryopreserved joint histopathology 
from arthritic mice demonstrated that MNP contrast is intracellular and specific for 
macrophages.  Tissue sections of the joints of the arthritic animals given MNP were stained 
and examined at 63X magnification.  MNP fluorescence was concentrated within the 
synovial tissue.  Macrophages stained with anti-MOMA2 had overlapping fluorescence with 
intracytoplasmic MNP, whereas lymphocytes (T-cells, B-cells) did not. 
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2.2.15 Tissue biodistribution of MNP in CIA mice 
 The tissue distribution of Gd(III) metal ions was measured by harvesting organs for 
direct current plasma elemental analysis.  Gadolinium is not an endogenous element that is 
present in physiological systems, so there is no background signal from biological tissues.  
Organs that commonly collect particulate matter were selected for analysis: lung, spleen, and 
liver; but also organs which may elucidate clearance mechanism: kidney, small intestine, and 
colon.  Figure 2.17 shows the biodistribution of MNP as measured by Gd elemental analysis 
of a CIA animal injected with 2.5 mg MNP.  Lung, kidney, and spleen demonstrated little to 
no detectable Gd(III).  
 
 
Figure 2.17 Biodistribution of MNP (2.5 mg injected dose, 4% Gd) in CIA mouse has been 
determined by DCP elemental analysis. 
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 Another arthritic animal, injected with 5.0 mg MNP, demonstrated similar 
distribution of MNP within its tissues.  Again, the clearance mechanism of the RES resulted 
in high levels of nanoparticle uptake.  Gd(III) levels approximately doubled in the liver 
compared to the animal injected with 2.5 mg MNP (Figure 2.18).  Liver uptake was, as 
expected, dose dependant to the amount of MNP injected (corresponding to the 4% Gd 
coverage of MNP as determined by DCP measurements).   
 
 
Figure 2.18 Gd levels measured in the livers of CIA animals injected with 2.5 mg MNP and 
5.0 mg MNP.  Elemental analysis of liver shows dose dependant uptake of MNP as 
correlated to milligrams of Gd in liver. 
 
Arthritic, inflamed paws of this animal were analyzed for Gd content to demonstrate high 
levels of Gd within a small tissue volume.  Figure 2.19 shows Gd levels roughly correlated 
with optical measurements of the paws.   
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 Figure 2.19 Gd levels measured in arthritic paws by elemental analysis were proportional to 
the increase in luminescence of MNP. 
 
 
These results show that MNP retains Gd and luminescence after being injected and traveling 
to the disease site.  CIA mice were also injected with a related MRI contrast enhancing 
nanomaterial reported by our group.66  This nanoparticle is also silica based with Gd(III) 
immobilized onto its mesoporous surface using the DTTA ligand.  Injecting 5.0 mg of these 
nanomaterials into CIA mice, the RES (liver and spleen) was found to contain a majority of 
the Gd(III), with the inflamed paws uptaking over 10% of the total Gd(III) injected.  The 
inflamed forepaws contained 1.64% (right) and 1.73% (left) while the larger hindpaws 
contained 3.40% (right) and 3.75% (left) of the total Gd(III) (Figure 2.20).  This level of 
uptake is extraordinary considering the small volume of inflamed synovial tissue and 
demonstrates the high payload and labeling efficiency of the nanomaterials. 
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Figure 2.20 Gd levels measured in arthritic paws by elemental analysis of collagen-induced 
arthritis animals injected with mesoporous silica nanospheres. 
 
The liver contained high levels of Gd(III) as a result of resident Kupffer cells 
(macrophages) quickly filtering particulate matter from the blood circulation.  Small amounts 
of Gd(III) were detected in the small intestine and colon, potentially indicating slow 
clearance of the MNP by a biliary mechanism.  Presumably, nanoparticles were filtered from 
the blood and collected by the liver, where they are slowly released with bile into the 
gastrointestinal system.  Silica nanospheres labeled with fluorescent molecules injected into 
mice were also found in the liver and bile ducts (Figure 2.21).66  Additionally, animals 
monitored over 4 weeks showed Gd(III) retained in the liver without detrimental effects to 
survival, demonstrating the robust nature of MNP while ensuring safe use. 
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A.  B.  
Figure 2.21 Silica nanospheres labeled with rhodamine injected into mice were found in the 
liver.  A) Light microscopy overlay with rhodamine fluorescence shows presence of 
nanospheres in bile ducts near Kupffer cells.  B) Immunofluorescence overlaying MOMA2-
FITC stained macrophage Kupffer cells trapping rhodamine labeled nanospheres. 
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2.3 Concluding Remarks 
 Early diagnosis of subclinical inflammation is realized by harnessing nanoscience of 
newly developed multifunctional nanomaterials.  These studies show that MNP contrast 
agent composed of a dye-doped silica nanoparticle with an enhanced paramagnetic coating of 
a Gd-DPTA silane derivative can deliver large payloads with enhanced relaxitives and thus 
be used as a highly sensitive noninvasive tool in inflammatory disease.  Murine monocytes 
could uptake and become labeled by MNP.  MNP-labeled cells were subsequently imaged in 
vitro by confocal and MRI, to show potential clinical application.  Current clinical studies 
have shown that T1 and T2 relaxation time mapping can rapidly detect cartilage changes 60-63 
and loss of proteoglycan density in cartilage. 63-65 Nanoscale materials can specifically label 
phagocytic cells because of these cells’ inherent activity for uptake and clearance of 
particulate matter.  Rather than avoiding the reticulo-endothelial system, we use the cellular 
mechanism to our advantage for diagnostic purposes using a robust hybrid nanomaterial.  
Our data provides evidence for high resolution T2 MRI and T2 relaxation time map changes 
at the cellular level in a model of autoimmune disease with dampening of the T2 signal in 
inflamed joints of arthritic animals.  Furthermore, multiple modalities of the MNP 
fluorescent core enabled us to demonstrate a strong positive correlation (p < 0.01) with 
clinical disease activity and determine the cellular target as infiltrating monocytes into the 
synovial tissue.  The MNP found in the liver was dose dependent, like MNP luminescence in 
the paws, and showed evidence of clearance by a biliary mechanism.  This novel technology 
has broad-reaching implications in guiding the diagnosis and treatment of autoimmune 
diseases such as rheumatoid arthritis in addition to other inflammatory disorders such as 
atherosclerosis and malignancy where targeted biologic therapy at the cellular level is 
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advancing.  It also serves as a platform for validating future molecular and cellular targets 
with the multifunctionality of the silica-based core for carrying cargo such as luminophores 
or therapeutic drugs. 
 
2.4 Materials and Methods 
2.4.1 Multimodal nanoparticle contrast agent  
The nanoparticle contrast agent was prepared by a synthetic procedure previously 
described.39  Briefly, vigorously stirred luminophore-doped (Ru(bpy)3Cl2: excitation maxima 
450 nm and emission maxima 595 nm) silicon dioxide nanoparticles prepared by water-in-oil 
reverse microemulsion are functionalized with Gd-(trimethoxysilylpropyl)- 
diethylenetriamine tetraacetate.  After purification, the hybrid contrast agent is dispersed in 
sterile saline (0.9%) and ready for administration as a functional MNP contrast agent.  In a 
clinical 3.0 Tesla MR imaging scanner, the r1 and r2 were measured to be 2.0 x 105 (mM Gd 
s)-1 and 6.1 x 105 (mM Gd s)-1, respectively. 
 
2.4.2 Cell culture studies 
 Monocyte immortalized lines were generated using the previously described methods 
of Monner67 and Walker68 with minor modifications described by Lorenz et al69.   Briefly, 
bone marrow progenitor cells from C57Bl/6 mice were harvested and grown in conditioned 
medium containing 10% heat-inactivated fetal calf serum, 1% l-glutamine, and 20% 
LADMAC (catalog no. CRL 2420; American Type Culture Collection) supernatant in 
Minimal Essential Medium.  Once immortalized, cells were grown in the aforementioned 
conditioned medium, which provides the isolated monocytes with colony-stimulating factor-
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1.  Cell lines were matured over 9 months to achieve a homogeneous population expressing 
the macrophage/monocyte marker MOMA-2 with phagocytic capacity.   
An alternate immortalized mononuclear cell line was cultured for viability and uptake 
experiments.  These mouse monocyte-macrophages, adapted to culture from female BALB/c 
mouse tumor, were grown in conditioned DMEM/F12 medium containing 10% heat-
inactivated fetal bovine serum and 1% Penicillin/Streptomycin at 37ºC with 5% CO2.  
Subcultures were prepared by scraping to dislodge cells rather than trypsinization. 
 
2.4.3 Monocyte cell viability assays 
 Cell viability of monocytes incubated in the presence of various nanoparticles was 
measured using the CellTiter 96® AQueous One Solution Cell Proliferation Assay purchased 
from Promega.  This is a colorimetric assay based on the bioreduction of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt 
(MTS) into a colored formazan product.  Manufacturer’s directions were followed for this 
assay with slight modifications for addition of nanoparticle incubation.  Briefly, 5000 cells 
per well were placed in a 96-well plate with 100 μL of media per well.  Nanoparticles were 
added in various concentrations in 20 μL volumes to each well.  Variable concentration 
ranges were used, and each concentration was replicated five times.  After addition of 
nanoparticles, cells are allowed to incubate and uptake nanoparticles for 20-24 hours at 37ºC 
with 5% CO2.  MTS reagent was subsequently thawed from 20ºC storage at 37ºC for 10 
minutes before 20 μL per well and incubated for 4 hours.  Absorbance at 490 nm was 
measured using a Bio-Rad 96-well plate reader.  Data was processed through insertion of raw 
data into a spreadsheet. 
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2.4.4 In vitro MRI acquisition of MNP-labeled monocyte pellet 
 Monocyte cells were trypsinized for 5 minutes at 37 ºC and 5% CO2 before 
collection, then concentration by low speed centrifugation.  Cell concentration was 
determined by the trypan blue exclusion assay. Approximately 18.1 x 106 monocytes were 
placed in a culture dish with 1 mL of media and 0.433 mL of nanoparticle solution (24.6 
mg/mL). After 1 hour of incubation, the cells were washed with fresh media twice and 
pelleted. A final layer of PBS (200 μL) was added on top, careful not to disturb the pellet, for 
MR imaging of the cells.  In vitro MRI was acquired on a 3.0T clinical scanner using T1- and 
T2- weighted sequences. Upon completion of MR imaging, the cells were digested in 1.0 M 
HNO3 for DCP measurements of the total Gd uptake by the cells. 
 
2.4.5 Confocal fluorescence microscopy of MNP-labeled monocytes 
 Monocyte cells were incubated in media (2.0 mL) with nanoparticle suspension (17.0 
µL, 24.6 mg/mL) for 30 minutes at 37 ºC with 5% CO2.  The cells were isolated from the 
media by centrifugation at 1000 RPM for 10 minutes at 4 ºC, and subsequently washed with 
fresh aliquots of media.  The resulting isolated pellet was suspended in 100 µL of PBS and 
approximately 15 µL was placed onto a glass slide for imaging.  Grease was used to create a 
protective barrier, to prevent crushing of cells and loss of buffer solution, before a glass 
cover slip was placed onto the slide.  A Leica SP2 AOBS Upright laser scanning confocal 
fluorescence microscope at the UNC Michael Hooker Microscopy Facility was used with 
instrument settings of excitation at 488 nm and emission detected using a 530 long pass filter 
setting at 252X zoom (63X oil immersion optical + 4X digital). 
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2.4.6 Flow cytometry of MNP-labeled monocytes 
One million monocyte cells were incubated in media (2.0 mL) with nanoparticle 
suspension (17.0 µL, 24.6 mg/mL) for 30 minutes at 37 ºC with 5% CO2.  The cells were 
isolated from the media by centrifugation at 1000 RPM for 10 minutes at 4 ºC, and 
subsequently washed with fresh aliquots of media.  The resulting isolated pellet was 
suspended in 1 mL PBS before placing into flow cytometer.  A Beckman-Coulter (Dako) 
CyAn ADP flow cytometer using 488 nm excitation and PE-Texas Red emission settings was 
used for acquisition and Summit software used for data analysis.  Cells incubated without 
nanoparticles are used as a control and for gating purposes.  Various concentrations of 
nanoparticle were incubated with monocytes to demonstrate uptake and labeling efficiency to 
trigger events via cell fluorescence. 
 
2.4.7 Induction and evaluation of collagen induced arthritis (CIA) in animals 
Collagen induced arthritis animal models are widely used and well characterized for 
studying rheumatoid arthritis.70-73  First generated in rats, CIA in mouse models is most 
widely used, particularly for testing new anti-inflammatory and immune-specific 
therapeutics.74  Genetically susceptible animals are immunized with type II collagen to 
induce T- and B-lymphocyte immunity.  Also, major histocompatibility complex (MHC) 
class II, a large protein expressed on the surface of cells that displays antigens, is associated 
with both CIA and RA.72  Further evidence of pathogenesis of this experimental disease has 
also been studied to draw parallels to RA for determining applicability to human disease.  
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Etiology of RA remains largely unknown, yet collagen II specific antibodies have been 
detected in RA patients, indicating the significance of this model.   
Animals used in these experiments were DBA-1J mice either purchased from Jackson 
Laboratories (Bar Harbor, ME) or bred and cared for in Division of Laboratory Animal 
Medicine (DLAM) facilities under the University of North Carolina approved Institutional 
Animal Care and Use Committee (IACUC) protocol number 05-289.0 in pathogen free 
specific conditions.  Eight week old DBA-1J mice were immunized with adjuvant (Complete 
Freund's on day 0 and incomplete Freund’s on day 21) ± 100µg per mouse of heterologous 
bovine type II collagen.  Using a 27 gauge needle, 0.1 mL of a 1:1 mixture of adjuvant + 
collagen or saline was injected subcutaneously into the base of the tail.  Mice were assessed 
at baseline and from the onset of arthritis by a clinical scoring index.  Clinical index was 
performed by a blinded observer with the following scoring system: 0 = normal paw; 1 = 
mild but definite swelling of either the ankle or digits; 2 = moderate redness and swelling of 
an ankle ± any number of digits; 3 = maximal redness and swelling of the entire paw and 
digits.  The maximum score per paw obtainable was 3 with a total score obtainable of 12 per 
mouse.  At experiment termination, hindlimbs were embedded in OCT and frozen in liquid 
nitrogen for immunofluorescence. 
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Figure 2.22 DBA-1J mouse was used for collagen-induced arthritis model.  Upper right inset 
shows a visual comparison of the increased swelling resulting from hind paw inflammation. 
 
2.4.8 Global assessment of disease 
Paw swelling measurements consist of the mouse’s fore- and hind-limbs in 
millimeters with a caliper.  The change in paw thickness from the baseline (day 0) for each 
individual mouse is recorded.  Results are reported as an average of change from baseline for 
each group.  Clinical Index of disease is a clinical measurement of the degree of arthritis 
severity that has been validated in previous experiments.75  The clinical index is based on 
scores assessed by a trained observer and takes into account arthritis that is present beyond 
the ankle swelling, such as individual toes or tenosynovium (Table 2.1).  Each paw is 
assessed by a blinded observer; maximum score is 3 per paw for a total of 12 per mouse.   
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Table 2.1 Clinical Index of arthritis 
 
 
Arthritis 
Score 
 
 
Clinical Presentation 
 
 
0 
 
Normal paw, no arthritis 
 
 
1 
 
Mild, but definite swelling and/or redness of one major joint (wrist or ankle) or 
toe involvement (any number) 
 
 
2 
 
Moderate redness and swelling of wrist or ankle ± any number of toes 
 
 
3 
 
Maximal redness and swelling of entire paw  including toes ± ankylosis 
 
 
 
2.4.9 Administration of multimodal nanoparticle contrast agent 
Twenty-four DBA-1J mice immunized with (n = 12) or without (n =12) type 
heterologous II bovine collagen were distributed randomly (n = 4 per group).  Animals were 
warmed approximately 5 minutes using a heat lamp to increase blood flow and visualization 
of the vein.  The animal was placed into a holding device before tail veil intravenous 
injection (0.05 mL) with saline or nanoparticle contrast agent (125mg/kg or 250mg/kg) in 
two doses separated by 12 hours on Day 35 or other specified time point.    Intravenous 
injection was chosen over intraperitoneal or subcutaneous injection to insure direct delivery to the 
blood circulation. 
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2.4.10 In vivo optical imaging and imaging analysis 
Fluorescence intensities of animals were collected using a Xenogen IVIS 100 series 
Optical/Fluorescence Scanner exciting with the GFP filter (445-490 nm) and collecting 
emission with the DsRed filter (575-650 nm).  Animals had images taken under anesthesia 
with a carefully monitored inhaled isoflurane/oxygen gas mixture.  Initially, animals are 
placed in an anesthesia chamber before transfer to the scanner.  A continual flow of 
anesthesia was administered by the instrument’s nose cone and the animal is positioned 
dorsal side up.  Paws were positioned away from the body to obtain clear optical and 
luminescence images of the arthritis.  Fluorescence images were taken 12 hours after the 
second injected dose of nanoparticle contrast agent.  Additional images were obtained at 36, 
60, and 84 hours after second injected dose.  Igor Pro 4.06 Living Image®, version 2.20.1 
was used to record images, normalize background, and select elliptical regions of interest 
(ROIs) for fluorescence quantification.  For each animal measurement, four ROI ellipses are 
placed to include the inflamed wrist or ankle and associated digits, before requesting the 
software for a measurement.  Scales are normalized at a minimum of 6500 counts and a 
maximum of 65000 counts, with background subtraction and cosmic correction.  The 
obtained data was placed into an excel (.xls) spreadsheet with paw swelling measurements 
and clinical indices of arthritis. 
 
2.4.11 In situ immunofluorescence 
Tissue sections (5-7 μm) were cut from Tissue-Tek® O.C.T. embedded hindlimbs 
using a CryoJane Cryostat (at -20 ºC) and analyzed using a Zeiss LSM5 confocal laser 
scanning fluorescent microscope.  Cold acetone was used for fixing tissue sections and 
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removing O.C.T. compound.  Immunofluorescence was performed with monoclonal 
antibodies targeting the following FITC-labeled antigens; anti-B220 (B cell) (BD 
Biosciences, San Jose, CA), -CD3 (T cell) (BD Biosciences, San Jose, CA) , -MOMA-2 
(monocytes/macrophages).  After incubation of tissue section with labeled monoclonal 
antibodies, washing steps using 1X phosphate buffered saline occurred.  Confocal laser 
scanning fluorescence microscopy images were taken using 488 nm excitation with 
emissions collected from 500-520 nm (FITC) and 575-625 nm (MNP).  Data was processed 
with Leica LCS software to minimize background and generate overlay images.   
 
2.4.12 MR Imaging and data analysis 
MR imaging studies were acquired on a 9.4T Bruker BioSpec small animal scanner 
(Bruker Biospin, Ettlingen, Germany) with a 35 mm quadrature radiofrequency transmit and 
receive coil.  Imaging of animals was performed under carefully monitored inhalational 
anesthesia of isoflurane/oxygen gas mixture.  Two sets of images were obtained on 3 animals 
with CIA after the onset of clinical disease; one prior to MNP contrast injection and the 
second 12 hours after the last of 2 doses of contrast was administered intravenously.  A 3D 
Fast Low Angle Shot (FLASH) gradient echo sequence was utilized to obtain high resolution 
anatomical images of both legs and paws of an animal. The imaging parameters were as 
follows, TR/TE=120/2.876 ms, flip angle = 30°, FOV = 32*32*12 mm3, Matrix Size = 
640*512*192, voxel size = 0.062 x 0.062 x 0.062 mm3.  Two-dimensional (2D) multiple 
echo spin echo sequence was used to estimate T2 maps.  In total, 32 echoes with an echo 
spacing of 3.7 ms were obtained. The first echo time was 3.7 ms. TR was 2000ms.  FOV and 
matrix size were set to 35x30 mm2 and 128 x 128.  The slice thickness was 1 mm.   T1 maps 
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were obtained with a variable TR rapid acquisition relaxation enhanced (RARE) sequence 
with a TE = 5.14 ms. Twelve variable TRs (TR = 50, 100, 300, 600, 1000, 1500, 2000, 2500, 
3000, 4000, 5000, 7000 ms) were used with a FOV of 35x30 mm2 and a matrix size of 128 x 
128. RARE factor was 3.   Data was analyzed by the following software: Bruker TOPSPIN, 
MRIcro, and InsightSNAP. 
 
2.4.13 Statistical data analysis 
The relationship between fluorescence and clinical disease at day 36 was analyzed 
using linear mixed models with fixed clinical disease and random mouse effects.  The 
methods of Lipsitz et al.76 were used to calculate partial correlation coefficients adjusted for 
random mouse effects.  Each mouse provides four data points derived from each inflamed 
paw, which is associated with the clinical assessment and the fluorescence counts measured 
from each ROI ellipse.   
 
2.4.14 Sample preparation for biodistribution studies.   
To quantify biodistribution of gadolinium associated with nanoparticles, 6-8 week old 
DBA/1J age / sex matched animals (Jackson Laboratory; Bar Harbor, ME) were injected 
intravenously with MNP.  Studies were approved by the UNC institutional animal care and 
use committee and housed and maintained by DLAM veterinary staff.  At desired timepoints, 
the animals were sacrificed by CO2 chamber and cervical dislocation.  Organs are harvested, 
and then cremated in a furnace at 500ºC for a minimum of 5 hours.  The resulting ash is 
dissolved in 1M HNO3 for elemental analysis. 
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CHAPTER 3 
 
 
SELF-ASSEMBLED HYBRID NANOPARTICLES FOR CANCER-SPECIFIC 
MULTIMODAL IMAGING 
 
 
3.1 Introduction 
In the previous chapter, a new nanomaterials with surfaced immobilized Gd(III) was 
presented for in vitro and in vivo imaging applications.  Large payloads of paramagnetic 
metal centers were immobilized onto the surface of the nanoparticle to take advantage of its 
high surface area.  As a comparison, we prepared nanoparticles with both a monolayer and 
multilayer of silane-derivatized Gd(III) chelates (Figure 3.1).  The two derivative 
nanoparticles produced excellent relaxivities, though the monolayer system produced the 
higher relaxivities per Gd(III) than the multilayer system. 199  Although the multilayer 
approach increased the payload of Gd(III) chelates, their MR relaxivities on a per Gd(III) 
basis diminished, presumably as a result of reduced water accessibility of the Gd(III) chelates 
buried in the interior of the multilayer.  This chapter presents a new electrostatic layer-by-
layer self-assembled nanoparticle platform for cancer-specific multimodal imaging. 
 92 
 
 
 
Figure 3.1 Hybrid silica nanoparticles for multimodal imaging with luminescent core and 
monolayer (left) or multilayer (right) surface coating of Gd(III) chelates. 
 
3.1.1 Electrostatic layer-by-layer self-assembly 
Assembly of multilayer films on solid surfaces has been studied for over 70 years to 
allow for fabrication of multifunctional architecture assemblies.  Initially, Langmuir-Blodgett 
(LB) films were thoroughly explored to for the deposition of organic molecules onto surfaces 
by immersion into liquids.  Multiple layers of aliphatic molecules could be formed with 
accurate control of thicknesses.  LB films, however, suffer from dependence on specific 
classes of molecules and specialized equipment.  Alternatives to LB films have since been 
developed,200, 201 one of the most well-studied being layer-by-layer (LbL) self-assembly. 
Nuzzo and Allara first reported LbL self-assembly with the adsorption of thiols on 
gold substrates.202  LbL self-assembly has since been further developed to utilize interactions 
of varying strength: covalent bonds,203 metal-ligand coordination,204 and electrostatic 
attraction of charged polyelectrolytes.115  First conceived as a method for developing layered 
films onto planar surfaces, electrostatic LbL self-assembly has been recently reported in 
core-shell nanostructures116, 205, 206 and nanoshells.207-210   
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Building multilayer films using oppositely charge polyelectrolytes has created many 
opportunities for new biofunctional coatings. Multilayer architectures can be created using 
synthetic (organic polymers, colloidal particles, inorganic complexes) or natural 
polyelectrolytes (proteins, polysaccharides, DNA.   Electrostatic LbL self assembly has 
found applications in thin film coating,211 micropatterning,212, 213 nanobioreactors,208, 214 
artificial cells,215 drug delivery,216, 217 and electronic devices.218, 219  Polyelectrolyte LbL 
adsorption is a general and versatile tool for creating multifunctional surface coatings using 
flexible macromolecules which can form defined superlattice architectures without 
crystallinity.115  Polyelectrolyte LbL self-assembly continues to remain an interesting method 
for development of new applications as the field expands toward nanomaterials. 
Gero Decher has used the well-characterized gold nanoparticle system to show the 
preparation of core-shell nanostructures with polyelectrolyte LbL self-assembly.205  
Subsequently, these core-shell structures could be converted to nanoshells.  Furthermore, 
fluorescent polyelectrolytes were used to characterize the LbL-gold nanoparticle system 
using fluorescence resonance energy transfer.116  Parameters, such as length and 
concentration of polyelectrolytes as well as ionic strength of the suspending solution, were 
investigated to optimize parameters for control of nanoparticle flocculation, aggregation, and 
stability.206  We hope to continue the development of functional polyelectrolyte LbL self-
assembly nanomaterial systems. 
By electrostatic layer-by-layer self-assembly, multilayers of Gd(III) containing 
polymer are formed and retain active magnetic centers for MR relaxation.  The disordered 
polyelectrolyte network allows for sufficient water molecule access to the Gd(III) centers.  
The network is built upon the previously mentioned fluorescent nanoparticle with a 
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monolayer of chelated Gd(III) (designated as MNP in Chapter 2).  Based upon the net 
negative surface charge of the MNP system, a newly developed Gd(III)-chelated polymer 
(positively-charged) and poly(styrene sulfonate) (PSS; widely used for LbL architectures as a 
negatively-charged polyelectrolyte) are used to assemble multiple layer pairs onto the 
nanoparticle surface. 
 
3.1.2 Targeting integrins 
Integrins are a family of cell surface receptors that attach cells to the extracellular 
matrix (ECM) to mediate the mechanical and chemical signals.220 The ECM is the protein 
network that provides structural support and regulates intercellular communication.  
Intimately linked to the architectural assembly of the actin filaments composing the 
cytoskeleton, multivalent integrin binding of the cell to the ECM causes integrin 
clustering,221 inducing changes in morphology and adhesion properties of the cell.  
Signaling mediated by integrins is fundamentally shared by virtually all tissues of 
multicellular animals.222  Binding of extracellular proteins to integrins can create a signal to 
the cell or the cell can create a signal to the integrin to bind extracellular proteins.223-226  Cells 
can use integrins to interact with the surrounding ECM to determine ideal conditions for 
survival.227  Interactions with the ECM may allow the cell to determine suitable conditions 
for growth, regardless of other exogenous signals for apoptosis.  Conversely, trauma to tissue 
may result in ECM damage, unsuitable conditions, to cue cell death.  Endothelial cells use 
integrins are the primary receptors for interacting with the ECM angiogenesis, or growth of 
new blood vessels.  During this process, integrins can signal endothelial cells to become 
more proliferative and invasive.228   
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Twenty-five years ago, Erkki Ruoslahti discovered the arginine-glycine-aspartic acid 
(RGD) sequence within fibronectin to be the essential recognition site for cell adhesion.229  
Later, it was realized that the three amino acid sequence was present in other adhesive 
proteins, such as laminin,230 fibrinogen,231 and vitronectin.232 The discovery of a conserved 
sequence contained within many adhesive proteins in conjunction with the study of integrins 
has led to significant advances in the understanding of cell signaling by surface receptors.  
Integrins contain two subunits of 15 α and 8 β that combine to form over 20 heterodimers for 
a variety of specificity and signaling toward such ECM and blood plasma proteins.   
RGD peptides can be designed to mimic specific adhesion proteins, thus binding the 
desired integrin target.  The RGD peptide sequence will bind non-selectively to more than 
one integrin receptor.  Affinity of the RGD sequence can be much lower than those 
specifically designed to target specific integrins.  For example, the GRGDSP sequence found 
in fibronectin binds 1000 times more effectively than RGD peptide.233  However, the RGD 
sequence alone can be very effective for targeting of many integrins. 
In tumor cell proliferation and growth, ligation of different integrins on tumor cells 
can modulate proliferation or apoptosis via the Bcl-2 cell survival pathway.234  The ανβ3 
integrin has been one of the most widely studied receptors in cancer cells, particularly for its 
role in angiogenesis.  On vascular cells of human tumors, these integrins are highly 
overexpressed.235, 236  Anti-ανβ3 monoclonal antibodies and RGD peptides could reduce 
growth of blood vessels in tumors in animal models, while antibodies specific for other 
integrins and scrambled peptides could not.236  Specifically, this study and others237 found 
that ανβ3 antagonists prevented growth of new blood vessels with no effect on pre-existing 
mature blood vessels.   
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The following work describes a RGD peptide with oligomeric lysine residues is 
electrostatically deposited onto the surface of the nanoparticle for the purpose of general 
targeting toward integrin receptors.  The positive charges of the consecutive lysine sequence 
interact with the anionic polymer layer on the nanoparticle to display the RGD sequence.  
The adsorption of many RGD peptides onto the surface of the nanoparticle generated a 
multivalency effect, well known throughout nanoparticle functionalization literature.238, 239  
The displayed RGD peptides targeted all integrins, but should preferentially target cancer 
cells due to the high overexpression of ανβ3 integrins.   
 
 
 
Figure 3.2 Two-dimensional cross-sectional schematic representation of polyelectrolyte 
layer-by-layer self assembly strategy using nanoparticle platform with anionic surface (MNP) 
to alternate deposition of Gd(III)-DOTA oligomer (blue) and PSS (yellow). 
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3.2 Results and Discussion 
3.2.1 Rationale 
 Silica nanoparticles doped with Ru(bpy)3Cl2 and monolayer coated with Gd(III)-
DTTA (MNP) was used as the platform for multilayer self-assembly.  The DTTA ligand has 
three tertiary amines and four carboxy groups to provide seven sites of coordination with a 
Gd(III) ion.  Two coordination sites remain open on the chelated Gd(III) ion for interaction 
with water.  As a result of the three positive charges of the Gd(III) and the four negative 
charges of the DTTA ligand, the net complex is anionic, rendering the surface of the 
nanoparticle as anionic (Figure 3.3).  The MNP particles thus provide an interesting starting 
point for depositing multilayers of cationic polymers of Gd(III) chelates to enhance the 
Gd(III) payload of each nanoparticle.  The versatility of the electrostatic LbL method also 
allows for the addition of charged oligomeric peptide sequences that can target cancer cells. 
 
 
 
 
Figure 3.3 Anionic net surface charge of MNP due to immobilization of anionic Gd(III)-
DTTA ligand onto the nanomaterials surface. 
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Using the resulting anionic surface of the nanoparticle, cationic Gd(III)-DOTA 
polymer was deposited onto the surface via electrostatic interactions.  Anionic polystyrene 
sulfonate (PSS) was subsequently deposited in order to provide a substrate for further 
polycation layers.  In a typical deposition step, MNP was treated with cationic Gd(III) 
oligomer before washing steps to remove weakly interacting oligomers.  The resulting 
cationic layer was followed with the interaction of anionic PSS, which was also washed to 
remove any weakly bound polyelectrolytes.  These alternating deposition steps were repeated 
to build up to seven bilayers of Gd(III) oligomer and PSS.  Figure 3.4 illustrates the LbL 
self-assembly strategy for building polyelectrolyte multilayer architectures.  These 
nanoparticles are designated NPnA or NPnB with n denoting surface termination with 
Gd(III)-DOTA oligomer and PSS, respectively. 
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3.2.2 Measurement of LbL multilayer growth 
 A variety of methods were used to demonstrate the multilayer growth of alternating 
polyelectrolytes on the nanoparticle surface.  These included the measurement of size, 
relaxivities, and fluorescence of the self-assembled multilayer growth.  Size was measured by 
TEM.  MR measurements served to directly correlate Gd(III) levels on the nanoparticle to 
water proton relaxation efficiency.  Fluorescence derived from increasing layers of tagged 
Gd(III)-DOTA oligomer was also used to quantify growth and Gd(III) levels.  The multiple 
techniques convincingly demonstrated LbL self-assembly on nanoparticles. 
 
3.2.2.1 Measurement of nanoparticle diameters by transmission electron microscopy  
TEM images indicated alternate deposition of Gd(III)-DOTA oligomer and PSS onto 
the nanoparticles by growth of average diameters from no layers to seven layers of 
polyelectrolytes (Figure 3.5).   
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Populations of nanoparticles were measured to determine average diameters for each 
layer.  A linear increase nanoparticle diameter was determined, rising from 37 ± 1 nm to 44.5 
± 1 nm (Figure 3.6).  With increasing layers, TEM showed electrostatic cross-linking 
between nanoparticles.  These particles remained dispersible in water, though higher 
concentrations could lead to aggregation due to interactions between polyelectrolyte layers.  
The TEM images show particles as they are concentrated in populations during dehydration.  
 
Figure 3.6 Particle diameter plotted against increasing layers of Gd(III)-DOTA oligomer. 
 
3.2.2.2 Measurement of fluorescein-tagged multilayer growth 
A fluorescein isothiocyanate (FITC)-tagged Gd(III)-chelate polymer was synthesized 
in order to probe layer growth using fluorescence spectroscopy.  Upon excitation at 488 nm, 
the large Stokes’ shift of the Ru(bpy)3Cl2-doped nanoparticle produced emission at 615 nm 
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and did not overlap with the fluorescein emission at 515 nm.  Since the luminescence 
intensity at 615 nm is proportional to the nanoparticle concentration, the ratio of the 515 nm 
emission intensity to the 615 nm emission intensity is proportional to the number of FITC 
molecules on each nanoparticle.  The 515 nm channel was used to monitor washes following 
deposition steps to ensure removal of excess FITC-tagged Gd(III)-DOTA oligomer.  Figure 
3.7 shows that the ratio between 515 nm emission and 615 nm emission increases 
quadratically as more layers of Gd(III)-DOTA oligomer and PSS are deposited.  Since the 
surface area of the spherical nanoparticle scales quadratically to the particle diameter, this 
result is consistent to the linear increase in diameter.    
Decher and coworkers noted a non-linear increase in UV (225 nm) absorption for 
polyelectrolyte deposition of PSS onto colloidal gold nanoparticles.  The manuscript 
attributes the non-linear, vaguely exponential, growth of PSS absorbance to the increasing 
diameter and thus surface area.205  Our spherical nanoparticle also experiences a similar 
increase in diameter and surface area.  As Decher has shown in another recent publication,116 
fluorescent tagging of the polyelectrolyte yields higher sensitivity to clearly demonstrate 
exponential growth, much like the growth experienced in our system.   
Interlayer diffusion, the phenomenon in which species of a polyelectrolyte LbL 
system vertically diffuse through films during the assembly process, may partially explain 
the LbL assembly growth described by the polynomial curve.  Exponential layer growth is 
behavior characteristic of systems exhibiting interlayer diffusion, previously evidenced 
through fluorescence-labeled240 and radiolabeled241 polyelectrolytes.  As the polyelectrolyte 
interactions equilibrate through interlayer diffusion, the interactions may become weaker and 
more easily stripped by polyelectrolyte solutions used for deposition.  The interlayer 
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diffusion in our polyelectrolyte architecture may occur, though TEM and relaxivity 
measurements support linear diameter growth.  . 
 
Figure 3.7 Gd(III)-DOTA-FITC oligomer concentrations, measured by fluorescence, 
increases exponentially with multilayer growth.  
 
3.2.2.3 MR relaxivities of layer-by-layer self-assembled nanoparticles 
Longitudinal (r1) and transverse (r2) MR relaxivities for LbL nanoparticles were 
determined with up to seven layers of Gd(III)-DOTA oligomer.  Interestingly, relaxivity 
values for NPnA on a per Gd(III) basis remained essentially constant at r1 = 19.0 ± 1.7 mM-
1s-1 and r2 = 55.0 ± 5.0 mM-1s-1 regardless of the number of deposited layers of Gd(III)-
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DOTA oligomer.  This contrasted starkly with the previously reported covalently attached 
multilayer system using bis(silylated)-Gd(III)-DTPA, which exhibited diminished relaxivities 
on a per Gd(III) basis.199  The highly disordered and hydrophilic nature of Gd(III)-DOTA 
oligomer and PSS allows ready access of water molecules to the metal centers for efficient 
water proton relaxation.  On the basis of the size of the LbL particles, we further estimated r1 
and r2 relaxivities of NPnA on a per particle basis, which increased linearly as more layers 
of Gd(III)-DOTA oligomer were deposited (Figure 3.9 and Table 3.1).  LbL self-assembly 
offers a superb strategy for increasing nanoparticle MR relaxivities. 
 
 
Figure 3.8  MR relaxivities, r1 and r2, per Gd(III)  for cationic Gd(III)-DOTA oligomer. 
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Figure 3.9 MR relaxivities, r1 and r2, per Gd(III) for LbL self-assembled nanoparticles. 
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Figure 3.10 Linear increase of r1 (black) and r2 (red) as layers of Gd(III)-containing 
oligomer are increased. 
 
3.2.3 Using electrostatic interactions to attach targeting moieties 
3.2.3.1 Description of the method 
 Since the LbL self-assembled nanoparticles were terminated with anionic PSS 
polymers, we hypothesized that the particles could be functionalized with targeting peptides 
that carry positive charges under physiological conditions.  The arginine-glycine-aspartate 
peptide sequence with seven consecutive lysine residues (K7RGD) was chosen for this study, 
with a glycine-arginine-aspartate derivative (K7GRD) serving as the scrambled control.  The 
negatively charged PSS layer could electrostatically interact with positively-charged lysine 
residues of the K7RGD sequence to display RGD peptides onto the surface of the PSS-
capped multilayer surface of the nanoparticles.  The RGD peptide is known to bind strongly 
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 Measurement of zeta potentials was performed to monitor changes in surface 
properties of the nanoparticles at various stages of multilayer growth and functionalization. 
Figure 3.12 shows that bare silica nanoparticles have negatively charged surfaces, as 
demonstrated with a zeta potential of -35.81 mV.  With the addition of the Gd(III)-DTTA 
monolayer coating, the zeta potential became more anionic to -42.45 mV.  Nanoparticles 
with three bilayers of Gd(III)-DOTA oligomer and PSS became more neutrally charged, -
25.83 mV.  Functionalization with the RGD or GRD peptides with lysine tail further shifted 
the zeta potential toward a cationic surface with zeta potential values of -18.98 and -17.79 
mV, respectively.  The oligomeric lysine tail interacts with the PSS surface, to create a more 
positive surface. 
 
 
Figure 3.12 Zeta potential (mV) measurements of bare silica nanoparticles, Gd(III)-DTTA 
monolayer covalent coated nanoparticles (MNP),  MNP with 3 bilayers, MNP with 3 bilayers 
and K7RGD functionalization, and MNP with 3 bilayers and K7GRD functionalization. 
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3.2.3.3 Targeting endothelial cells 
 Angiogenesis, the process of new blood vessel formation, has been widely researched 
for its involvement in tumor growth and metastasis.  Malignant tumor expansion and 
metastasis requires the neovasculature to supply nutrients, oxygen, and waste disposal.  
Endothelial cells line the interior of blood vessels for the circulatory system and play an 
obviously important role in angiogenesis.  Integrins, the primary receptors for endothelial 
cells in initiating proliferation and invasion, can be targeted through RGD peptides. 
Cow pulmonary artery endothelial (CPAE) cells have high expression of these 
integrin receptors.243  Luminescent imaging and targeting capability of LbL nanoparticles 
were confirmed by laser scanning confocal fluorescence microscopy.  As shown in Figure 
3.13, significant luminescence signal was observed for CPAE cells incubated with NP5B 
particles that were non-covalently functionalized with K7RGD sequence.  Little to no 
luminescent signal was observed for control CPAE: incubated without nanoparticles, 
incubated with unfunctionalized nanoparticles, and incubated with a scrambled binding site 
(K7GRD).  The resulting images correlate with the membrane flow model of cell 
migration.244  Cellular projections, lamellipodia and filopodia, extend from the cell’s 
migrating edge and have an abundance of integrins.  Serving as adhesion points and directing 
movement, integrins are closely linked to the actin network that shapes the cytoskeleton.244  
Thus, the RGD-labeled nanoparticles are localized at cellular projections and edges that 
display increased levels of integrins.   
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3.2.3.4 Targeting cancer cells 
Integrin receptors have been found to be overexpressed in HT-29 human colon cancer 
cells.245, 246  Previously, fluorescent albumin microspheres were labeled with K7RGD were 
reported to show integrin mediated uptake by HT-29 cells.247  Targeting capability of our 
LbL nanoparticles was initially determined by laser scanning confocal fluorescence 
microscopy.  As shown in Figure 3.14, significant luminescence signal was observed in HT-
29 cells incubated with NP5B particles that have been non-covalently functionalized with 
K7RGD sequence, indicating efficient targeting of HT-29 cells.  In comparison, little to no 
luminescent signal was observed for control HT-29 cells without nanoparticles and for cells 
that have been incubated with NP5B particles without functionalization or functionalized 
with K7GRD. 
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3.3 Concluding remarks 
 In summary, we have utilized electrostatic LbL self-assembly to prepare targeted 
multifunctional nanoparticles with both MR and optical imaging capabilities.  Electrostatic 
LbL self-assembly enabled increased loading of Gd(III) payloads and the preservation of 
efficient water proton relaxation by Gd(III) metal centers.  Multilayer growth was confirmed 
by electron microscope measurement of nanoparticle diameters, demonstration of increasing 
MR relaxivities, as well as increasing fluorescence.  The LbL self-assembly strategy not only 
affords nanoparticles with extraordinarily high MR relaxivities but also provides an efficient 
means for non-covalent functionalization with affinity molecules.  Specifically, a cationic tail 
was used to display an integrin specific targeting peptide sequence that could label cancer 
cells (HT-29) and cells that participate in angiogenesis (CPAE).  The generality of the 
polyelectrolyte LbL self-assembly should allow the design of imaging and/or therapeutic 
multifunctional nanoparticles that can specifically target a wide range of diseased cells.   
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3.4 Materials and Methods 
3.4.1 General 
All of the chemicals were obtained from commercial sources and used without further 
purification.  Solvents used in all the reactions were dried by standard procedures.248  
Multimodal nanoparticles were prepared as described previously.199  Poly(sodium-4-
styrenesulfonate) (PSS) MW = 70 kDa (Sigma-Aldrich) was used without further 
purification.  Poly-L-lysine was purchased from MP Biomedicals and used without further 
purification.  The water (dH2O) used in all experiments was prepared by a Millipore 
NanoPure purification system (resistivity higher than 18.2 MΩ cm-1) and autoclaved before 
use.  KKKKKKKRGD peptide was purchased from EZ Biolabs whereas KKKKKKKGRD 
peptide was prepared with an Applied Biosystems Pioneer peptide synthesizer using Applied 
Biosystems PEG-PAL amide resin.  Thermogravimetric analysis (TGA) was performed using 
a Shimadzu TGA-50 equipped with a platinum pan and heated at a rate of 3°C / min under 
air.  Gd(III) ion concentration was measured on an Applied Research Laboratories 
SpectraSpan7 Direct Current Plasma (DCP) Spectrometer.  T1 and T2 values were 
determined on a Bruker 3.0 Tesla full body Magnetic Resonance Imaging (MRI) Scanner.  
Confocal laser scanning microscope images were taken with a Zeiss LSM5 (488 nm 
excitation, 550-650 nm emission) at the University of North Carolina Michael Hooker 
Microscopy Facility.  Fluorescence microscope images were taken at the University of North 
Carolina Pharmacy School with a Zeiss Axiovert 100 TV Fluorescence Microscopy using a 
long pass FITC filter.  A JEM 100CX-II Transmission Electron Microscope (TEM) was used 
to determine particle size and morphology. 
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minutes before centrifugation at 14000 RPM for 20 minutes.  The supernatant was removed 
(Flow Through = FT), and the nanoparticle pellet was re-suspended in 1 mL of dH2O.  
Centrifugation/re-suspension was repeated twice (Wash 1 = W1, Wash 2 = W2) before the 
washed nanoparticle pellet was re-suspended into the original volume (250 μL).  The 
collected supernatant fractions and re-suspended nanoparticle suspension were measured for 
fluorescence (515 nm and 610 nm) to ensure that the nanoparticles were free from excess 
unbound materials.  To deposit the negatively charged PSS layer, 250 μL of the previously 
layered nanoparticle was placed into 250 μL and 500 μL PSS (1 mg/mL dH2O).  The 
previous process was repeated to obtain the desired stage of layer deposition using constant 
concentrations of PSS and 1 or 1a.  This LbL deposition was repeated for depositing more 
layers of 1 (1a) and PSS. 
 
3.4.4 Functionalization of layer-by-layer nanoparticles 
A 50 μL aliquot of 3 or 5 bilayer nanoparticle (NP3B or NP5B) was placed in a 1.5 
mL polypropylene Eppendorf tube and 2 μL of KKKKKKKRGD, KKKKKKKGRD, or 
poly-lysine (1mg / μL) was added.  The tube was placed in a sonicator for 20 minutes before 
being centrifuged for 20 minutes at 14000 RPM.  The supernatant was removed and the 
nanoparticles were re-dispersed in 50 μL of dH2O.  The centrifugation / re-dispersion step 
was repeated once more before being re-dispersed in 50 μL of dH2O for use as labeling 
agent. 
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3.4.5 Endothelial cell culture 
 Cow pulmonary artery endothelial (CPAE) cells were maintained at 37°C in a 5% 
CO2 incubator with EMEM containing 20% FBS and 1% Penicillin/Streptomycin. All cells 
were passed and overgrowth maintained by trypsinization for detachment of adherent cells 
from the surface of the flasks.  Fresh media was added to flasks for continued growth of 
culture. 
 
3.4.6 Colon carcinoma cell culture 
Human colon carcinoma (HT-29) cells were maintained at 37°C in a 5% CO2 
incubator with McCoy’s 5A containing 10% FBS and 1% Penicillin/Streptomycin.  Cells 
were passed and overgrowth maintained by trypsinization to detach adherent cells from the 
surface of the flasks before aspiration and refreshing of media. 
 
3.4.7 In vitro labeling and fluorescence imaging of live endothelial and cancer cells 
CPAE and HT-29 cells were grown on 6-well plates with sterile glass coverslips at 
37°C in a 5% CO2 incubator with EMEM containing 20% FBS and 1% P/S, and McCoy’s 
5A containing 10% FBS and 1% P/S, respectively.  Cells were incubated with functionalized 
and unfunctionalized nanoparticle concentration of 11 μg/mL for 15-60 minutes.  The cells 
were then washed extensively with Hank’s Balanced buffered Saline Solution (HBSS) before 
being immediately imaged by scanning laser confocal fluorescence microscopy.   
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3.4.8 In vitro MRI of nanoparticle-labeled cancer cells 
HT-29 cells were cultured in large dishes with McCoy’s 5A media containing 10% 
FBS and 1% P/S at 37°C with 5% CO2 until approximately 70% confluency was observed.  
Cells were incubated with and without KKKKKKKRGD-functionalized, KKKKKKKGRD-
functionalized, and unfunctionalized 3-layer nanoparticles (11 µg/mL) for 60 minutes.  The 
cells were extensively washed with HBSS before trypsinization.  Free floating cells were 
counted using trypan blue exclusion (~10 million cells per dish), before collection and 
centrifugation at 1000 RPM for 10 minutes.  The cell pellets were placed into small PCR 
tubes with 100 µL of HBSS on top for MR imaging.   
 
3.4.9. Zeta potential measurements 
Zeta potentials of these materials were measured using a Brookhaven Instruments 
Corporation ZetaPlus Zeta Potential Analyzer.  Each sample was suspended in a 1 mM KCl 
aqueous solution (pH 7.0) to achieve ~0.1 mg/mL concentration.  Measurements were 
conducted at 25ºC and run a minimum of ten times.  The average values for various samples 
are determined and standard deviations are reported using error bars.   
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3.4.10 Determination of relaxivities per layer  
Nanoparticles with 3 layers of cationic Gd(III)-DOTA polymer was used to determine 
the Gd(III) amounts for layer relaxivity calculations. 
 
1) Mass % Gd for 3 layers of cationic polymer:  
2.96% Gd (as determined by TGA) 
2) Diameter of silica nanoparticle:  
37 nm (as determined by TEM) 
3) Calculated volume of silica nanoparticle (SiNP):  
(4/3)×π×(radius)3 = (4/3)×π×(37 nm/2)3 = 2.65×10-17 cm3 
4) SiO2 density:  
2.0 g cm-3 
5) Calculated mass of silica nanoparticle:  
2.65×10-17 cm3 × 2.0 g cm-3 = 5.30×10-17 g SiNP-1 
6) Gd atoms per nanoparticle:  
(Y×mGd) / (mSiNP +Y×moligomer + PSS) = mass % Gd 
 
(Y×157.25 g mol-1) 
= 2.96 % _______________________________________________________ 
 
(5.30×10-17 g SiNP-1 × 6.022×1023 SiNP mol-1) + (Y×669.3 g mol-1) 
 
Y×137.45  = 9.44×105 
Y = 6870 Gd per SiNP 
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NP0 was previously determined to have ~10200 Gd(III) ions immobilized onto its 
surface.199  Using TGA to determine weight loss of organics (from polymers), the number of 
Gd(III) ions of each layer was approximated.  Given the calculated number of Gd(III) ions 
within 3 layers of cationic polymer on the surface of Gd-DTTA functionalized nanoparticles 
we could determine the approximate number of Gd(III) ions per volume to be 0.822 taking 
into account the change in particle diameter found by TEM measurements.  Gd(III) 
relaxivities of each successive layer deposition did not show appreciable change in 
relaxivities.  Thus, we could average the relaxivities and multiply the number of Gd(III) per 
particle by the average relaxivities on a per Gd(III) basis to obtain relaxivities on a per 
particle basis.   
For NP3A,  
r1 = (10200 + 6870) Gd(III) ions per NP3A × 19 mM Gd s-1 = 3.24 × 105 (mM-1 s-1) 
r2 = (10200 + 6870) Gd(III) ions per NP3A × 55 mM Gd s-1 = 9.39 × 105 (mM-1 s-1) 
 
 
Table 3.1 Estimated MR relaxivities on a per particle basis (105 mM-1 s-1) 
  
NP0 
 
NP1A 
 
NP2A 
 
NP3A 
 
NP4A 
 
NP5A 
 
NP6A 
 
NP7A 
 
r1 
 
1.94 
 
2.11 
 
3.00 
 
3.24 
 
3.95 
 
4.29 
 
4.75 
 
5.34 
 
r2 
 
5.61 
 
6.11 
 
8.69 
 
9.46 
 
11.4 
 
12.4 
 
13.8 
 
15.5 
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CHAPTER 4 
 
HIGHLY-EFFICIENT PURIFICATION OF NATIVE HEXAHISTIDINE-TAGGED 
RECOMBINANT PROTEINS BY MULTIVALENT NITRILOTRIACETIC ACID-
MODIFIED MAGNETIC NANOPARTICLES 
 
 
4.1 Introduction 
Therapeutic proteins are undergoing rapid growth in pharmaceutical use in recent 
years.  Proteins are of primary importance to enzymatic and structural biochemical functions 
and control cell signaling, cell adhesion, and immune responses.  These abilities make 
proteins topics of great interest for therapy and treatment of diseases.  Additionally, the 
development of recombinant protein technology1 has allowed the production of many 
proteins of interest in large-scales.  Recombinant versions of proteins, such as human growth 
factor, human insulin, insulin-like growth factor, and interferon, have replaced therapeutics 
previously harvested from human and animal organs.   
As the demand for protein therapeutics increases, an emerging need exists for more 
efficient protein purification techniques allowing for direct isolation of proteins from cell 
lysates.2  Among many currently used protein purification strategies,3 immobilized metal 
affinity chromatography (IMAC) has emerged as one of the most powerful techniques for the 
purification of recombinant proteins.4  In the most common IMAC implementation, a 
hexahistidine (His×6) tag, comprised of six consecutively placed histidine residues, is 
incorporated into the C- or N-terminus of a recombinant protein.  The His×6 tag binds 
strongly to a divalent metal chelate, such as the Ni(II) nitrilotriacetate complex (Ni-NTA), 
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which is immobilized on a convenient commercial resin.  Four of the six coordination sites 
on the octahedral Ni(II) center are occupied by the NTA ligand and the remaining 
coordination sites are occupied by two of the six imidazole moieties available in the His×6 
tag.5 
 
Figure 4.1  Open sites of Ni(II) center open for imidazole (histidine) coordination. 
This basic IMAC strategy allows the purification of recombinant His×6-tagged 
proteins in one or two steps to achieve a moderate degree of purity.  Moreover, the His×6 tag 
is relatively small and generally does not interfere with the native structure or function of the 
protein and, is thus commonly used without cleavage of the tag.  Since its discovery in late 
1980’s, Ni-NTA based IMAC has been widely used for purifying recombinant proteins and 
many His×6-tagged proteins are now commercially available.  While this strategy has proven 
to be fairly successful, a significant percentage of recombinant proteins remain difficult to 
purify by IMAC.6  Low protein expression is a key contributor to difficulties in protein 
isolation. The target protein concentration may be less than 0.1% of the cleared crude lysate 
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when overexpressed in E. coli, and much lower when overexpressed in mammalian cells.  
Numerous functionally active proteins can only be expressed in mammalian cells and this 
imposes new challenges to protein purification techniques.  The target protein structure may 
also add to purification difficulties by blocking the His×6-tag from the Ni-NTA moiety on 
the surface of commonly used commercially available microbeads.  Consequently, a large 
number of His×6-tagged proteins cannot be captured by commercial Ni-NTA resin under 
native conditions.  To overcome this problem, purification under denaturing conditions has 
been used to gain full access to the His×6-tag, but the overall protein purification efficacy 
significantly decreases because of the unreliability and inefficiency of in vitro protein re-
folding to their native functional conformations. 
Significant efforts have been devoted to gaining a better understanding of the Ni-
NTA/His×6-tag interactions and thus improving the IMAC protein purification efficiency 
over the past few years.  Recently, the strength of the Ni-NTA interaction to histidine-tagged 
peptides was probed and assessed using scanning force microscopic techniques.7  Here, the 
benefit of tags with increased histidine residues was examined, and showed that His×6-tag 
created a significantly more stable interaction than His×2-tag (two histidine residues).  
Others have used His×10-tags to attempt to achieve higher affinity with a variety of designed 
Ni-NTA molecules.8  These studies appear to indicate the histidine tag affinity to Ni-NTA 
does not benefit from redundancy greater than His×6 due to increased loss of entropy. 
In an alternate viewpoint, Ebright et al. has elegantly demonstrated enhanced binding 
of the His×6-tag to a bivalent Ni-NTA system over a monovalent Ni-NTA control using 
fluorescence anisotropy and fluorescence resonance energy transfer measurements. 9  Tampé, 
Piehler, and coworkers have further studied the enhanced affinity of multivalent Ni-NTA-
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on iron oxide nanoparticles indicated a similarly high affinity for His×6-tagged proteins, 
suggesting that the very high density of the mono-NTA chelate presented by the 
nanoparticles allows the binding of the His×6-tag to more than one NTA moiety on the 
surface.  This work thus demonstrates that the multivalency strategy can be utilized to 
enhance the binding of his-tagged proteins in their native, folded conformations.   
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4.2 Results and Discussion 
4.2.1 Surface Modification of Iron Oxide Nanoparticles with Bis-NTA and Mono-NTA 
Ni(II) Chelates 
The iron oxide magnetic nanoparticles were synthesized using protocols previously 
described.19-21  The nanoparticles were washed in ethanol and transferred into n-hexanes and 
used without further purification.  The concentration of the nanoparticles was estimated 
based on the dry mass after the removal of the solvents.  Iron oxide nanoparticles prepared by 
different routes gave similar results for protein binding and purification experiments. 
Although a number of functional groups have been immobilized on iron oxide 
nanoparticles, their binding strength and their ease of surface immobilization vary 
significantly.  Since Xu and co-workers recently demonstrated the efficient immobilization of 
dopamine derivatives on iron oxide nanoparticles,16 we have decided to use this strategy to 
immobilize bis-NTA Ni(II) chelate for protein purifications.  The new bis-NTA ligand with a 
catechol group (4) was synthesized according to the procedures outlined in the previous 
section.  Compound 4 was synthesized in 22% overall yield in 4 steps starting from known 
benzyl-protected dopamine trifluoroacetate salt and benzene-1,3,5-tricarbonyltrichloride.  
New compounds 1-4 were characterized by 1H and 13C{1H} NMR spectroscopy and mass 
spectrometry. 
In order to determine the effects of multivalency on protein binding, we have also 
prepared a new mono-NTA ligand with two catechol groups (8) by using a 1:1 ratio of 
dopamine hydrochloride and benzene-1,3,5-tricarbonyltrichloride as shown in Scheme 2.  
Compound 8 was synthesized in an overall yield of 28% in 4 steps.  New compounds 5-8 
were characterized by 1H and 13C{1H} NMR spectroscopy and mass spectrometry. 
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Surface modification of iron oxide nanoparticles with new NTA-derived ligands was 
accomplished by simply stirring a biphasic mixture of the ligand in water and iron oxide 
nanoparticles in hexanes.  The NTA-ligand-immobilized nanoparticles were charged with 
Ni(II) ions by ultrasonic mixing in 2M NiCl2.  The iron oxide nanoparticles with different 
coatings were characterized by transmission electron microscopy (TEM).  TEM images of 
~10 nm monodisperse iron oxide nanoparticles (prepared by thermal decomposition) before 
and after surface modifications illustrate the retention of nanoparticle size and shape, and 
monodispersity throughout monovalent and bivalent NTA-ligand surface modification and 
Ni(II)-loading.  Slight aggregation of Ni(II)-loaded nanoparticles was however observed in 
the TEM images (Figure 4.4). 
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Figure 4.4 TEM images of monodisperse iron oxide nanoparticles (10 nm in diameter): (A) 
Prepared by thermal decomposition and stabilized with oleic acid. (B) Modified with bis-
NTA ligand. (C) Ni(II)-loaded bis-NTA nanoparticle. (D) Modified with mono-NTA ligand. 
(E) Ni(II)-loaded mono-NTA nanoparticle. The scale bar is 50 nm. 
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4.2.2 Binding of His×6-tagged Proteins Labeled with [35S]-Methionine 
Immobilization of proteins onto the nanoparticles and subsequent elution were 
initially demonstrated with His×6-tagged, [35S]-methionine-labeled GMAP-210 protein 
synthesized via coupled in vitro transcription and translation.  In a typical binding-elution 
experiment, the direct lysate (DL) signal is equal to the sum of the flow through (FT), washes 
(W1, W2, W3), elutions (E1, E2), and residual resin signals.  The signal from each fraction 
was measured using liquid scintillation counting (Figure 4.5, Table 4.1).  
 
Figure 4.5  Graphical representation the results of an [35S]-labeled HisX6-GMAP-210 
binding radioactive scintillation counting assay for bis-Ni-NTA nanoparticles (solid bars) and 
commercial Ni-NTA agarose beads (open bars). Fractions collected and radioactivity 
quantified in counts per minute (CPM). DL = direct lysate, FT = flow through, W1 = wash 1, 
W2 = wash 2, W3 = wash 3, E1 = elution 1, E2 = elution 2. 
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Table 4.1  Raw counts per minutes (CPM) data from [35S]-labeled HisX6-GMAP-210 
binding radioactive scintillation counting assay for bis-Ni-NTA nanoparticles and 
commercial Ni-NTA agarose beads (DL = direct lysate, FT = flow through, W1 = wash 1, 
W2 = wash 2, W3 = wash 3, E1 = elution 1, E2 = elution 2). 
 
Blank 
(CPM) 
DL 
(CPM) 
FT 
(CPM) 
W1 
(CPM) 
W2 
(CPM) 
W3 
(CPM) 
E1 
(CPM) 
E2 
(CPM) 
Resin 
(CPM) 
Bis-Ni-NTA 
Nanoparticles 
38 1685170 1636552 39410 1980 653 3840 764 1971 
Commercial 
Beads 85 1685170 1500000 60783 490 248 3602 430 269 
 
 
Since only a small percentage of  [35S]-methionine was incorporated into the 
recombinant protein in the TNT reaction, a majority of the radioactivity in both the 
commercial beads and nanoparticle systems came from unbound free [35S]-methionine in the 
FT (Figure 4.5 and Table 4.1).  Following the removal of FT, the resin was washed three 
times until low background was reached and subsequently eluted with imidazole. This 
scintillation counting assay demonstrates that the NTA-modified nanoparticles can 
specifically capture His×6-tagged proteins followed by efficient elution with imidazole. We 
also examined the relative protein binding capacity of nanoparticles as compared to the 
commercial beads. It was found that the 10 μL (0.32% v/v suspension, assuming Fe3O4 
density of 5.15 g/cm3) of nanoparticle (16.3 mg/mL) had a similar binding capacity to 10 μL 
(5% v/v suspension) of commercial magnetic agarose beads.  It appears that the un-optimized 
nanoparticles used in this work have higher residual radioactivity after elutions when 
compared to the commercial beads, presumably due to relatively strong nonspecific binding. 
This result was within expectation, since the commercial beads were coated with agarose, 
which has low non-specific binding to proteins. We think that the non-specific binding of the 
nanoparticle could be minimized if its surface is modified with hydrophilic molecules such as 
PEG that are known to resist nonspecific protein binding.22 
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4.2.3 Binding of Overexpressed His×6-tagged Proteins 
We next carried out protein binding studies of several commercially available 
recombinant His×6-tagged proteins. One of the major problems in using Ni-NTA in protein 
purification is that numerous His×6-tagged proteins can only be purified under denaturing 
conditions. Consequently, a complicated refolding process is needed that often results in low 
yield of the active protein. In this work, we focus on examining whether the NTA-modified 
nanoparticles can be used under native conditions to purify His×6-tagged proteins that 
require denaturing conditions when commercial NTA beads are used. We used recombinant 
murine His×6-endostatin as an example. Endostatin is a potent angiogenesis inhibitor that has 
shown therapeutic suppression of tumor-induced angiogenesis in mice implanted with 
tumors.23  O’Reilly et al. reported that recombinant murine endostatin with His×6 tag could 
be expressed in E. coli as insoluble inclusion bodies and purified using Ni-NTA resin under 
denaturing conditions. Endostatin thus purified underwent an inefficient refolding process 
before it could be used in xenograft mouse studies. We found that the already folded 
endostatin could not be captured when commercial Ni(II)-NTA beads were used. As shown 
in Figure 3, approximately 90% of His×6-rmES was present in the FT, and almost no protein 
was detected in the elutions, indicating that commercial beads failed to capture His×6-rmES 
under native conditions.  Significantly, Ni(II)-loaded nanoparticles readily bound His×6-
rmES without the use of denaturing conditions.  A 10 μL volume of Ni(II)-loaded 
nanoparticles (163 μg) is found to have a binding capacity of 5.6 μg under un-optimized 
conditions.  The bound His×6-rmES was readily eluted by imidazole.  This result indicates 
that milligrams of a native protein can be purified using approximately 30 mg of Ni(II)-
loaded nanoparticles (Figure 4.6 and Table 4.2).  
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Figure 4.8 (A) Bright field (left) and corresponding confocal fluorescence microcopy (right) 
images of normal cow pulmonary artery endothelial (CPAE) cells (without 6×His-rmES 
treatment). (B) Bright field (left) and corresponding confocal fluorescence microcopy (right) 
images of apoptotic CPAE cells labeled with Annexin V-PE. Apoptosis was induced over 24 
hours using 6×His-rmES (10 μg/mL) eluted from bis-Ni-NTA nanoparticles. 
 
 Additionally, bis-Ni-NTA nanoparticles were used to bind His×6-caspase 3, the key 
mediator of apoptosis in mammalian cells, and demonstrate retention of activity after elution.  
After typical binding/elution of the His×6-caspase 3, the resulting fractions were used for an 
activity assay of a fluorogenic substrate containing the caspase 3-specific sequence (Figure 
4.9).  Activity was shown in the untreated protein (DL) and the unbound protein (FT).  Little 
activity was found in the final wash before elution (W3), suggesting that unbound protein has 
been washed away.  The first elution showed an apparent fluorescence due to activity of the 
caspase 3.  The second elution showed little fluorescence, suggesting that most of the 
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elutable protein was release in the first elution fraction.  The nanoparticle resin also showed 
activity, demonstrating that protein immobilized onto the surface of the nanoparticle retains 
activity. 
 
 
Figure 4.9 His×6-caspase 3 activity of fractions from binding/elution experiment with bis-
Ni-NTA nanoparticles.  RLU was measured from the fluorescence resulting from the 
cleavage of the DEVD-APC substrate. 
 
We also compared the binding of other His×6-tagged proteins that do not require 
denaturing conditions for Ni-NTA based purifications.  Ubiquitin is a protein found 
throughout all eukaryotic cells and plays key roles in highly specific protein degradation.  
The small His×6-tagged ubiquitin (9.3 kDa) is expected to have an affinity for both the 
commercial beads as well as the surface modified nanoparticles.  SDS-PAGE analysis 
confirms the affinity of the commercial beads and the Ni(II)-loaded nanoparticle (Figure 
4.10 and Table 4.2).    
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Densitometry analysis shows the binding capacity of 20 μL (5% v/v suspension) of 
commercial beads is 1.1 μg His×6-Ub, while that of 10 μL (0.32% v/v suspension) of bis-
NTA-Ni(II)-loaded nanoparticle is 2.3 μg.  In comparing the binding of 10 μL (0.32% v/v 
suspension) of nanoparticle for His×6-rmES (21.3 kDa , 5.6 μg) and 6xHis-Ub (9.3 kDa , 2.3 
μg), it is estimated that the binding capacity of the Ni(II)-loaded nanoparticles is approximate 
25 pmol of proteins/μL. 
 
Table 4.2 Intensity Density Values (%IDV) compiled from densitometry quantification of 
SDS-PAGE results for collected fractions comparing Bis-Ni-NTA-modified nanoparticles 
and commercial Ni-NTA agarose beads in HisX6-tagged protein binding experiments (10 μg 
total protein). 
 FT W1 W2 W3 E1 E2 NP/resin 
6xHis-rmES + 2NiNTA-NP 30.48 1.05 1.70 0.67 56.20 1.21 8.70 
6xHis-rmES + Com. Beads 89.58 6.06 0.44 0.44 0.54 0.18 2.74 
6xHis-Ub + 2NiNTA-NP 26.30 6.06 0.44 0.44 0.54 0.18 11.54 
6xHis-Ub + Com. Beads 39.35 18.22 9.80 3.07 23.21 7.85 6.54 
6xHis-UCH-L1 + 2NiNTA NP 31.80 12.38 1.25 1.16 34.78 3.30 15.33 
6xHis-UCH-L1 + Com. Beads 83.16 6.19 0.89 0.89 0.58 0.03 8.27 
 
 
Binding studies on His×6-UCH-L1 (~25 kDa) were also used to demonstrate the 
nanoparticle’s ability to capture His×6-enzymes (Figure 4.11 and Table 4.2).  Binding 
capacities of 40 μL (5% v/v suspension) of commercial beads and 10 μL (0.32% v/v 
suspension) of nanoparticle are 0.06 μg and 3.48 μg His×6-UCH-L1, respectively.  This 
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method in volume reduction. However, the loss of purified proteins could be significant, 
presumably due to nonspecific interactions with the membrane. Our Ni(II)-loaded 
nanoparticles disperse well in aqueous solution, and therefore significantly smaller elution 
volume can be used. This advantage eliminates the need of volume reduction and makes it 
possible to directly use the proteins after purification. 
Our magnetic, recyclable nanoparticles are able to bind important His×6-proteins in 
native conformations with a high capacity. It is worth mentioning that our Ni(II)-loaded 
nanoparticles were able to efficiently capture all the proteins we randomly chose for this 
study. Although we have only tested a small number of proteins, our success rate is much 
higher than that of previous research, which has shown an approximately 60% success rate.5 
 
4.2.4 Purification of Recombinant His×6-tagged Proteins from Crude Mammalian Cell 
Lysate 
Proteins expressed in mammalian cells are usually soluble and active, and therefore 
extremely useful in studying their physiological significances. The biggest drawback is that 
their expression levels are very low, making the purification challenging.  The nanoparticle 
platform was previously used for protein purification from E. Coli cell lysate,15 in which 
proteins are much more easily overexpressed.  We investigated whether our NTA-loaded 
nanoparticles could be used to purify recombinant proteins expressed in mammalian cells. 
293T cells were used to express a recombinant His×6-UGT protein. The lysate was prepared 
for purification of 6xHis-UGT protein by the bis-Ni(II)-NTA modified nanoparticles.  Figure 
4.12 shows the staining of DL, FT, W3, E1, E2, and nanoparticle fractions and clearly 
indicates the purification of desired His×6-tagged protein from the mammalian crude lysate.  
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The elution E1 is significantly cleaner than the direct lysate, with few impurities.  These 
nonspecifically bound impurities are probably due to proteins with many amino acid residues 
that can coordinate to the immobilized metal ion.  Nonetheless, the present nanoparticle 
system has shown great promise in the purification of His×6-tagged proteins from crude 
mammalian cell lysates. 
 
 
 
 
Figure 4.12 Mammalian Cell Lysate Fractionation. SDS-PAGE (12.5% separation gel) 
results of flag-6xHis-UGT prepared from 293T cells showing marker (M). direct lysate (DL, 
10% dilution), flow through (FT, 10%), 3rd wash (W3), elution 1 (E1), elution 2 (E2), and 
protein residue on nanoparticle (NP).   
 
4.2.5 Nonspecific Interactions 
Nonspecific interactions between the protein and nanoparticles do not appear to be 
significant when the NTA nanoparticles are chelated with N(II). Table 1 shows 
approximately 8.7% of His×6-rmES remained on the Ni(II) loaded bis-NTA-modified 
nanoparticles after elution, slightly higher than that on commercial microbeads.  Without the 
chelation of Ni(II), His×6-rmES was found to have a high affinity for the bis-NTA-modified 
nanoparticle (Figure 4.6).  Densitometry measurements show that more than 45% of the 
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6xHis-rmES was present in the sum of the washes and elutions, while 39% of the protein 
remained on the bis-NTA-modified nanoparticles.   
On the other hand, freshly prepared iron oxide nanoparticles (without surface 
modifications) had little interaction with His×6-rmES.  Over 70% of the 10 μg of loaded 
protein was detected in the FT and over 90% was detected in the sum of the FT and washes.  
The nanoparticles retained approximately 7% of the His×6-rmES after elution, a significant 
reduction from the 39% retention of Ni(II)-free bis-NTA-modified nanoparticles.  The 
nonspecific interaction of the rmES to the nanoparticle is thus a result of the surface 
modifications.  To rule out the potential role of residual oleic acid on the nanoparticle 
surface, we carried out a binding experiment using particles without oleic acid stabilization.  
Nonspecific interaction was observed for the oleic acid-free nanoparticles as well. 
As the ratio of His×6-rmES (μg) to bis-Ni(II)-loaded NTA nanoparticle (mg) is 
increased from 10.2 to 61.3, the amount of non-specifically bound protein appears to remain 
constant (Figure 4.13).  The specific his-tag binding to Ni(II)-NTA occurs after the full 
capacity of the nonspecific interaction is reached at a 6×His-rmES (μg) to bis-Ni(II)-loaded 
NTA nanoparticle (mg) ratio between 10.2 and 15.3.  Maximum binding capacity of the 
nanoparticle via the His×6-tag appears to have been reached with a His×6-rmES (μg) to bis-
Ni(II)-loaded NTA nanoparticle (mg) ratio of 61.3 since some 6xHis-rmES is detectable in 
the FT.  
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4.3 Concluding Remarks 
New bis-nitrilotriacetic acid (NTA) chelates with catechol anchors were synthesized and 
immobilized on superparamagnetic iron oxide nanoparticles.  When loaded with Ni(II), these 
NTA-immobilized nanoparticles were shown to bind His×6-tagged proteins in their native, 
folded conformations that commercial microbeads fail to bind under identical conditions.  An 
extensive series of control experiments suggest that the multivalency strategy can be utilized 
to enhance the binding of His×6-tagged proteins in their native, folded conformations.  
Additionally, proteins were confirmed for activity after binding and release by a fluorometric 
assay for enzymatic cleavage of a caspase 3-specific peptide sequence and induction of 
apoptosis of endothelial cells.  We further demonstrated the selective purification of His×6-
tagged proteins from direct cell lysates by using the Ni(II)-loaded magnetic nanoparticles.  
The present platform is capable of efficient purification of His×6-tagged proteins that are 
expressed at low levels in mammalian cells.  This work thus presents a novel nanoparticle-
based high-capacity protein purification system with shorter incubation times, proportionally 
large washes, and significantly smaller elution volumes compared to currently available 
microbeads.  
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4.4 Materials and Methods 
4.4.1 General 
Nα,Nα-bis(carboxymethyl)-L-lysine was purchased from Fluka.  All other chemicals 
were purchased from Sigma-Aldrich and used as received unless otherwise noted.  Carboxy-
terminated magnetic microparticles were purchased from Bangs Laboratories, Inc. Purified 
recombinant His×6-endostatin (His×6-rmES) was purchased from Calbiochem. Recombinant 
human His×6-ubiquitin (His×6-Ub) and mouse His×6-ubiquitin C-terminal hydrolase L-1 
(His×6-UCH-L1) were from Boston Biochem.  1H and 13C{1H} NMR spectra were obtained 
on a Bruker 400MHz AVANCE or Bruker 400MHz DRX.  Mass spectra were obtained from 
Voyager DE-Pro MALDI-MS or HP/Agilent LC/Ion-trap MS in the Department of 
Chemistry at Duke University.  Liquid scintillation counting experiments are performed on a 
Tri-Carb 2900TR Liquid Scintillation Analyzer.  SDS-PAGE gels were quantified using the 
AlphaEaseFC program.  Transmission Electron Microscopy (TEM) images were taken with a 
JEM-100CXII transmission electron microscope at 100 KV.   
 
4.4.2 Synthesis of 2-(3,4-Bis-benzyloxy-phenyl)-ethylamine-trifluoroacetate-salt (Bn-
DA-TFA) 
2-(3,4-Bis-benzyloxy-phenyl)-ethylamine-trifluoroacetate-salt (Bn-DA-TFA) was 
prepared from literature procedures.16  Briefly, dopamine hydrochloride was neutralized by 
stirring with NaOH in dioxane.  Tert-butyl dicarbonate dioxane solution was dropped into the 
stirring solution while solution was cooled in an ice bath.  The solution was allowed to stir 
for under inert atmosphere and allowed to warm to room temperature.  The solution was 
acidified with an HCl solution and subsequently washed with ethyl acetate.  The tert-butyl 
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carbonate (tBOC) protected product was concentrated, purified by column chromatography, 
and confirmed using 1H NMR spectroscopy.  The tBOC-dopamine was dissolved in 
anhydrous DMF and stirred vigorously with K2CO3.  Excess benzyl bromide was added 
dropwise and allowed to stir overnight.  The reaction mixture was filtered and washed with 
ether, dH2O, and brine.  The benzyl protected tBOC-dopamine was purified by 
recrystallization and confirmed by 1H NMR spectroscopy.  The tBOC deprotection was 
removed by stirring the fully protected compound in 5% trifluoroacetic acid (TFA) in 
dichloromethane.  The solvents were evaporated under reduced pressure to yield the benzyl 
protected dopamine TFA salt, which was confirmed by 1H NMR spectroscopy. 
 
Scheme 4.1   2-(3,4-Bis-benzyloxy-phenyl)-ethylamine-trifluoroacetate-salt (Bn-DA-TFA) 
synthesis. 
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4.4.3 Synthesis of Nα,Nα-bis(carboxymethyl)-L-lysine tribenzyl ester-trifluoroacetate-
salt (Bn-NTA-lys-TFA) 
Nα,Nα-bis(carboxymethyl)-L-lysine tribenzyl ester-trifluoroacetate-salt (Bn-NTA-lys-
TFA) prepared from literature procedures.17  Briefly, Nα,Nα-bis(carboxymethyl)-L-lysine and 
Cs2CO3 were stirred vigorously in H2O and dioxane.  Tert-butyl dicarbonate dioxane solution 
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was dropped into the stirring solution while solution was cooled in an ice bath.  The 
completion of the reaction was checked using thin layer chromatography (TLC) and 
ninhydrin.  The tBOC-protected lysine derivative cesium salt was filtered dried under 
reduced pressure to remove solvent.  The intermediate protected cesium salt product was 
dissolved in DMF before excess benzyl bromide was slowly dropped into solution.  The final 
protected product was extracted using chloroform and washed with water before column 
chromatography and 1H NMR confirmation.  The tBOC protection group was removed by 
TFA in dichloromethane to from the benzyl protected lysine derivative TFA salt, which was 
confirmed by 1H NMR spectroscopy. 
 
Scheme 4.2 Nα,Nα-bis(carboxymethyl)-L-lysine tribenzyl ester-trifluoroacetate-salt (Bn-
NTA-lys-TFA) synthesis. 
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4.4.4 Synthesis of dimethyl 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-
dioate (1).  
To a stirring solution of benzene-1,3,5-tricarbonyltrichloride (1.7 g, 6.40 mmol) in 
dry CH2Cl2 (170 mL) at 0°C was added Bn-DA-TFA (0.536 g, 1.20 mmol) in dry CH2Cl2 
(100 mL) dropwise over 5 hours.  The solution was allowed to warm to room temperature.  
The solvent was removed under reduced pressure to produce a white residue.  Methanol was 
added and stirred for a few hours.  The excess methanol was removed under reduced pressure 
to produce a white solid.  The product was isolated using flash column chromatography 
(ethyl acetate/hexanes, 2:3 v/v; Rf = 0.4).  The solvents were removed under reduced 
pressure to yield a white solid of 1 (0.225 g, 0.408 mmol, 34.0% yield).  1H NMR (400MHz, 
CDCl3): 8.75 (s, 1H), 8.52 (s, 2H), 7.40 (d, 4H), 7.29 (m, 6H), 6.90 (d, 1H), 6.81 (s, 1H), 
6.72 (d, 1H), 5.11 (s, 2H), 5.01 (s, 2H), 3.92 (s, 6H), 3.64 (q, 2H), 2.83 (t, 2H); 13C NMR 
(CDCl3, 100 MHz) δ 165.4, 165.3, 149.0, 147.6, 137.2, 137.0, 135.4, 132.9, 132.0, 131.9, 
130.9, 128.3, 127.7, 127.2, 121.5, 115.5, 115.3, 71.3, 71.2, 52.4, 41.4, 34.9, 31.5; MALDI-
MS: [M+H]+ m/z 554.0 (calcd 554.6); [M+Na]+, m/z 577.2 (calcd 576.6); [M+K]+ m/z 592.8 
(calcd 592.7). 
 
Scheme 4.3   Dimethyl 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioate (1) 
synthesis. 
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4.4.5 Synthesis of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioic acid (2) 
To a stirring solution of 1 (0.160, 0.289 mmol) in acetone (6 mL) was added 1N 
NaOH (4 mL).  After 3 hours, complete deprotection was confirmed by TLC.  The solution 
was acidified to pH 3 using 1N HCl.  The solvent was removed and the product was stirred in 
H2O.  The precipitate of 2 was collected by suction filtration and recrystallized in acetone 
(0.145 g, 0.276 mmol, 95.5% yield).  1H NMR (400MHz, MeOD): 8.42 (s, 1H), 8.21 (s, 2H), 
7.15-6.90 (m, 10H), 6.67 (s, 1H), 6.62 (d, 1H), 6.49 (d, 1H), 4.73 (s, 4H), 3.28 (t, 2H), 2.54 
(t, 2H); 13C NMR (DMSO, 100 MHz) δ 166.4, 164.6, 148.3, 146.8, 137.5, 137.4, 135.5, 
132.7, 132.2, 132.0, 131.8, 128.4, 127.8, 127.7, 127.6, 127.5, 121.2, 115.2, 114.8, 70.3, 70.2, 
41.1, 34.4; MALDI-MS: [M+H]+ m/z 525.9 (calcd 526.6). 
 
Scheme 4.4   5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioic acid (2) synthesis. 
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4.4.6 Synthesis of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-benzyl-NTA-
lysine (3) 
The diacid 2 (0.140 g, 0.266 mmol) was stirred in dry CH2Cl2 (13 mL) to form a 
cloudy suspension.  0.40 mL of SOCl2 was slowly added and stirring continued at 50 °C for 6 
hours to form a clear solution.  The solvent was removed under reduced pressure to give the 
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5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-dioyl dichloride intermediate which 
was used without further purification.   
To a stirring mixture of Bn-NTA-lys-TFA (0.408 g, 0.632 mmol), TEA (0.5 mL), and 
CHCl3 (5 mL) was added a solution of 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-
1,3-dioyl dichloride in CHCl3 (10 mL) dropwise at 0 °C.  The reaction was allowed to warm 
to room temperature and stir overnight.  After removal of solvents under reduced pressure, 
column chromatography (ethyl acetate/hexanes, 3:2 v/v; Rf = 0.5) was used to isolate a pure 
white solid of 3 (0.281 g, 0.181 mmol, 67.9% yield).  1H NMR (CDCl3, 400 MHz) δ 8.33 (s, 
3H), 7.41-7.25 (m, 35H), 6.95 (t), 6.86 (d, 2H), 6.80 (s, 2H), 6.69 (d, 2H), 5.10 (s, 8H), 5.06 
(s, 2H), 4.98 (s, 4H), 3.68 (s, 4H), 3.59 (t, 4H), 3.46 (t, 1H), 3.32 (t, 2H) 2.75 (t, 4H), 1,69-
1.24 (m, 6H); 13C NMR (CDCl3, 100 MHz) δ 172.8, 171.7, 166.3, 149.3, 148.0, 137.6, 137.5, 
135.9, 135.8, 135.6, 135.4, 132.4, 128.8, 128.7, 128.6, 128.5, 128.0, 127.7, 121.7, 116.2, 
115.9, 71.6, 66.8, 66.7, 64.5, 53.1, 40.2, 35.4, 29.9, 28.5, 23.1; MALDI-MS: [M+H]+ m/z 
1556.3 (calcd 1555.8); [M+Na]+, m/z 1577.5 (calcd 1577.8); [M+K]+, m/z 1593.1 (calcd 
1593.9). 
 
 
 
 
  
162 
 
Scheme 4.5 5-(3,4-bis(benzyloxy)phenethylcarbamoyl)benzene-1,3-benzyl-NTA-lysine (3) 
synthesis. 
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4.4.7 Synthesis of 5-(3,4-bis(hydroxy)phenethylcarbamoyl)benzene-1,3-NTA-lysine (4) 
Product 3 (0.043 g, 0.052 mmol) was dissolved in 1.5 mL of CHCl3 and 6 mL of 
MeOH and placed in a Parr flask with 15 mg Pd/C (10%).  The mixture was shaken in a Parr 
reactor for 24 hours under H2 (60 psi).  Upon complete deprotection, the palladium catalyst 
was filtered off using Celite and solvent removed under reduced pressure.  The product was 
purified by recrystallization in MeOH/CH2Cl2 to give 4 in a quantitative yield.  1H NMR 
(MeOD, 400 MHz) δ; 8.29 (s, 3H), 6.60 (s, 1H), 6.59 (s, 1H), 6.47 (d, 2H), 3.71-3.21 (m, 
16H), 2.68 (t, 2H), 1.63-1.45 (m, 8H), 1.18 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ; 174.1, 
173.0, 168.6, 146.7, 144.7, 136.6, 132.0, 130.0, 121.1, 117.0, 116.4, 66.9, 54.3, 43.1, 40.7, 
35.9, 29.8, 29.8, 24.4; MALDI-MS: [M]+, m/z 833 (calcd 833.8); [M+Na]+, m/z 856 (calcd 
856.8). 
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 Scheme 4.6  5-(3,4-bis(hydroxy)phenethylcarbamoyl)benzene-1,3-NTA-lysine (4) synthesis. 
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4.4.8 Synthesis of methyl 3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoate (5) 
 To a stirring solution of benzene-1,3,5-tricarbonyltrichloride (0.320 g, 1.20 mmol) in 
dry CH2Cl2 (170 mL) at 0 °C was added Bn-DA-TFA (0.536 g, 1.20 mmol) in dry CH2Cl2 
(100 mL) dropwise over 5 hours.  The solution was allowed to warm to room temperature.  
The solvent was removed under reduced pressure to produce a white residue.  Methanol was 
added and allowed to stir for a few hours.  The excess methanol was removed under reduced 
pressure to produce a white solid.  The product was isolated using silica flash column 
chromatography (ethyl acetate/hexanes, 1:1 v/v; Rf = 0.4).  The solvents were removed under 
reduced pressure to yield a white solid of 5 (0.298 g, 0.349 mmol, 29.0% yield).  1H NMR 
(CDCl3, 400 MHz) δ 8.44 (s, 2H), 8.28 (s, 1H), 7.45-7.25 (m, 20H), 6.88 (d, 2H), 6.81 (s, 
2H), 6.71 (d, 2H), 6.56 (t, 2H), 5.10, (s, 8H), 3.88 (s, 3H), 3.60 (q, 4H), 2.80 (t, 4H); 13C 
NMR (CDCl3, 100 MHz) δ 165.6, 165.3, 148.7, 147.4, 136.9, 136.8, 135.1, 131.9, 130.5, 
130.3, 129.6, 128.2, 127.6, 127.2, 127.1, 121.4, 115.4, 115.0, 71.1, 52.2, 41.3, 34.7; MALDI-
MS: [M+Na]+, m/z 877.0 (calcd 878.0); [M+K]+, m/z 893.0 (calcd 894.1). 
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Scheme 4.7  Methyl 3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoate (5) synthesis. 
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4.4.9 Synthesis of 3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoic acid (6) 
Compound 5 (0.250 g, 0.292 mmol) was stirred in a solution of 3 mL of acetone and 
1 mL of 1M NaOH overnight.  The solution was acidified to pH 3 using 1N HCl, added 
dropwise.  The solvent was removed and the product was stirred in H2O.  The precipitate was 
collected by vacuum filtration to give 6 in quantitative yield.  1H NMR (MeOD, 400 MHz) δ 
8.53 (s, 2H), 8.37 (s, 1H), 7.40-7.20 (m, 20H), 6.93 (s, 2H), 6.91 (s, 2H), 6.76 (d, 2H), 5.03 
(s, 8H), 3.54 (t, 4H), 2.81 (t, 4H); 13C NMR (CDCl3, 100 MHz) δ 169.2, 164.9, 150.4, 148.9, 
138.9, 138.8, 136.3, 134.3, 131.9, 129.8, 129.5, 128.9 128.8, 123.1, 117.2, 116.9, 72.7, 72.5, 
42.8, 37.0; MALDI-MS: [M+Na]+, m/z 863.4 (calcd 864.0). 
 
Scheme. 4.8   3,5-bis(3,4-bis(benzyloxy)phenethylcarbamoyl)benzoic acid (6) synthesis. 
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4.4.10 Synthesis of benzyl 6-(N3,N5-bis(3,4-bis(benzyloxy)phenethyl)benzene-1,3,5-
tricarboxamido)-2-(bis(((benzyloxy)carbonyl)methyl)amino)hexanoate (7) 
A mixture of Bn-NTA-lys-TFA (0.060 g, 0.071 mmol), 6 (0.075 g, 0.142 mmol), and 
HOBt (0.010 g, 0.074 mmol) was stirred in 3 mL anhydrous DMF for 5 minutes.  
Dicyclohexylcarbodiimide (0.015 g, 0.073 mmol) was added and the mixture was allowed to 
stir overnight.  The solvents were removed under reduced pressure.  The product 7 was 
isolated with silica gel flash column chromatography (ethyl acetate/hexanes, 3/2 v/v; Rf = 
0.4).  Yield: 0.094 g (97.7%). 1H NMR (CDCl3, 400 MHz) δ 8.43 (s, 1H), 8.41 (s, 2H), 7.50-
7.26 (m, 40H), 7.04 (s, 3H), 6.87 (s, 1H), 6.85 (d, 1H), 6.72 (d, 1H), 5.12 (s, 8H), 5.07 (s, 
8H), 3.74 (s, 8H), 3.59 (t, 2H), 3.51 (t, 2H), 3.35 (t, 4H), 2.79 (t, 2H), 1.75-1.28 (m, 12H); 
13C NMR (CDCl3, 100 MHz) δ 172.5, 171.5, 165.9, 148.9, 147.6, 137.2, 137.1, 135.3, 132.0, 
128.5, 128.4, 128.3, 128.2, 128.1, 127.7, 127.4, 127.3, 121.5, 115.7, 115.2, 71.3, 66.5, 66.4, 
64.0, 52.8, 41.5, 39.9, 35.0, 27.9, 25.5, 24.8; MALDI-MS: [M+H]+, m/z 1356.4 (calcd 
1355.6); [M+Na]+, m/z 1378.0 (calcd 1378.6); [M+K]+, m/z 1393.9 (calcd 1394.7).  
 
Scheme 4.9 Benzyl 6-(N3,N5-bis(3,4-bis(benzyloxy)phenethyl)benzene-1,3,5-
tricarboxamido)-2-(bis(((benzyloxy)carbonyl)methyl)amino)hexanoate  (7) synthesis. 
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4.4.11 Synthesis of 6-(N3,N5-bis(3,4-dihydroxyphenethyl)benzene-1,3,5-tricarboxamido)-
2-(bis(carboxymethyl)amino)hexanoic acid (8) 
To a solution 7 (0.094 g, 0.069 mmol) in of 5 mL of MeOH and 10 mL of CHCl3 was 
added 20 mg Pd/C (10%).  The mixture was placed in a Parr reactor bottle and rocked for 24 
hours at 60 psi H2.  Upon complete deprotection, the catalyst was filtered off using Celite and 
the solvents were removed under reduced pressure.  8 was purified by recrystallization in 
MeOH/CH2Cl2 in a quantitative yield.  1H NMR (MeOD, 400 MHz) δ 8.34 (s, 3H), 6.69 (s, 
2H), 6.67 (s, 2H), 6.56 (d, 2H), 3.64 (t, 4H), 3.60 (t, 1H), 3.33 (s, 4H), 3.29 (t, 2H), 2.77 (t, 
4H), 1.90-1.50 (m, 4H), 1.27 (p, 2H); 13C NMR (CDCl3, 100 MHz) δ; 175.3, 174.1, 168.5, 
146.1, 144.7, 136.6, 132.0, 129.4, 121.1, 117.0, 116.4, 68.2, 55.1, 43.1, 40.3, 35.9, 26.4, 25.9, 
23.6.  MALDI-MS: [M+H]+, m/z 724.8 (calcd 725.7); [M+Na]+, m/z 746.8 (calcd 747.7). 
 
Scheme 4.10  6-(N3,N5-bis(3,4-dihydroxyphenethyl)benzene-1,3,5-tricarboxamido)-2-
(bis(carboxymethyl)amino)hexanoic acid (8) synthesis. 
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4.4.12 Surface modification of iron oxide nanoparticles with bis-NTA-derived Ni(II) 
chelate and mono-NTA-derived Ni(II) chelate 
The ligand 4 (0.5 mL of a 10 mg/mL MeOH solution) was placed in 1.25 mL dH2O 
of pH 4.  To this aqueous solution was added 1 mL of iron oxide nanoparticles in n-hexanes 
(16.3 mg/mL).  The two layers were sonicated for 1 hour, and repeatedly washed with n-
hexanes, then methanol until the nanoparticles were readily dispersed in dH2O.  Using a 
magnet, the nanoparticles were collected and placed in 2 mL of dH2O.  The bis-NTA-pendant 
ligand-immobilized nanoparticles (0.5 mL) were placed in 2M NiCl2 solution and sonicated 
for 1 hour.  The Ni(II)-loaded nanoparticles were stored in the NiCl2 solution before use.  
Iron oxide nanoparticle modified with mono-NTA Ni(II)-loaded nanoparticles were similarly 
prepared.   
 
Scheme 4.11 Surface modification of iron oxide nanoparticles with bis-NTA-derived Ni(II) 
chelate. 
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4.4.13 Preparation of Ni(II)-loaded magnetic microparticles 
An aliquot of 0.5 mL (2.4 μmol carboxyl) BioMag Carboxyl magnetic iron oxide 
microparticles (~1.5 μm mean diameter, ~20 mg/mL particle concentration, ~4.8 μmol/mL 
carboxy-surface titration, Bang’s Lab) was washed with dH2O (3×500 μL), then with acetone 
(3×500 μL).  Aliquots of N-hydroxysuccinimide (NHS) (25 μL, 30 mg/mL acetone) and 
dicyclohexylcarbodiimide (50 μL, 50 mg/mL acetone) were added and incubated overnight.  
The NHS-activated particles were washed with acetone and used without further purification. 
A 240 μM solution of Nα,Nα-bis(carboxymethyl)-L-lysine was prepared by dissolving 
0.629 mg Nα,Nα-bis(carboxymethyl)-L-lysine in 35 μL of triethylamine, 500 μL of acetone, 
and 500 μL of dH2O.  The NHS-activated microparticles were washed with dH2O, then 
placed in 100 μL of the Nα,Nα-bis(carboxymethyl)-L-lysine solution.  After overnight 
incubation, the particles were washed with dH2O.  The particles were placed in a 1M NiCl2 
solution for 1 hour before use. 
 
4.4.14 Isolation of recombinant mouse His×6-Endostatin (His×6-rmES) with Ni(II)-
loaded nanoparticles 
The Ni(II)-loaded nanoparticles (7-10 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and a binding buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM 
imidazole, pH 8.0).  The washed nanoparticles were incubated with 10 μg of His×6-rmES in 
40 μL of binding buffer for 5-60 minutes at 4 °C.  Using a centrifuge and magnet, the 
supernatant was collected and nanoparticles washed in 50 μL aliquots of binding buffer (FT: 
Flow Through, W1: Wash 1, W2: Wash 2, W3: Wash 3).  After the third wash, 50 μL of the 
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elution buffer (50 mM phosphate buffer system, 300 mM NaCl, 250 mM imidazole, pH 8.0) 
was added and the mixture tumbled for 10 minutes at 4 °C.  The eluents were similarly 
collected by centrifugation and magnetic immobilization (E1: Elution 1, E2: Elution 2).  
Non-specifically bound protein was released from the nanoparticles by boiling at 95 °C for 4 
minutes in a Laemmli SDS-PAGE gel loading buffer.  The volumes of the aliquots were 
reduced in a Speedvac before loading to an SDS-PAGE (12.5%, 180V, 50 min).  After 
separation, the SDS-PAGE gel was stained in a Coomassie Blue solution (0.1% Coomassie 
blue, 10% acetic acid, 40% methanol) overnight.  Recombinant human His×6-ubiquitin 
(His×6-Ub) and recombinant mouse His×6-ubiquitin C-terminal hydrolase L-1 (His×6-UCH-
L1) were isolated with Ni(II)-loaded nanoparticles in the same fashion. Protein isolation by 
commercial magnetic agarose beads was performed according to the manufacturer’s 
instructions (Qiagen). 
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Scheme 4.12 General scheme for bis-NTA nanoparticle protein purification system 
 
 
 
4.4.15 Isolation of His×6-rmES by Ni(II)-loaded microparticles 
The Ni(II)-loaded microparticles (10 μL, 20mg/mL) were washed in dH2O (3x50 μL) 
and binding buffer (3 x 50 μL).  The washed microparticles were incubated with 10 μg of 
His×6-rmES in 40 μL of binding buffer for 60 minutes at 4 °C.  The beads were washed and 
the bound protein eluted similarly. All the fractions were loaded to an SDS-PAGE for 
analysis as previously described. 
 
4.4.16 Expression of [35S]-methionine-labeled His×6-GMAP-210 
The gene coding a 70 kDa fragment of GMAP-210 (Golgi-associated microtubule-
binding protein) was PCR-amplified from a human total RNA library (Stratagene). After 
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introducing the T7 promoter and TMV 5’-UTR by second PCR, the cDNA was used as 
template for a coupled in vitro transcription/translation (TNT) reaction in the presence of 10 
µCi [35S]-methionine (Perkin-Elmer) in a total volume of 25 µL for 90 minutes at 30 °C. 
Protein synthesis was confirmed by SDS-PAGE and autoradiography. The protein was stored 
at –80 °C until used. 
 
Hisx6-GMAP-210 Properties: 
 
Protein Sequence: 
 
10 20 30 40 50 
MQLLFTITME KGEIEAELCW AKKRLLEEAN KYEKTIEELS NARNLNTSAL 
60 70 80 90 100 
QLEHEHLIKL NQKKDMEIAE LKKNIEQMDT DHKETKDVLS SSLEEQKQLT 
110 120 130 140 150 
QLINKKEIFI EKLKERSSKL QEELDKYSQA LRKNEILRQT IEEKDRSLGS 
160 170 180 190 200 
MKEENNHLQE ELERLREEQS RTAPVADPKT LDSVTELASE VSQLNTIKEH 
210 220 230 240 250 
LEEEIKHHQK IIEDQNQSKM QLLQSLQEQK KEMDEFRYQH EQMNATHTQL 
260 270 280 290 300 
FLEKDEEIKS LQKTIEQIKT QLHEERQDIQ TDNSDIFQET KVQSLNIENG 
310 320 330 340 350 
SEKHDLSKAE TERLVKGIKE RELEIKLLNE KNISLTKQID QLSKDEVGKL 
360 370 380 390 400 
TQIIQQKDLE IQALHARISS TSHTQDVVYL QQQLQAYAME REKVFAVLNE 
410 420 430 440 450 
KTRENSHLKT EYHKMMDIVA AKEAALIKLQ DENKKLSTRF ESSGQDMFRE 
460 470 480 490 500 
TIQNLSRIIR EKDIEIDALS QKCQTLLAVL QTSSTGNEAG GVNSHQFEEL 
510 520 530 540 550 
LQERDKLKQQ VKKMEEWKQQ VMTTVQNMQH ESAQLQEELH QLQAQVLVDS 
560 570 580 590 600 
DNNSKLQVDY TGLIQSYEQN ETKLKNFGQE LAQVQHSIGQ LCNTKDLLLG 
610 620 630 640  
KLDIISPQLS SASLLTPQSA ECLRASKSEV LSEHHHHHH_    
 
Number of amino acids: 639 
 
Molecular weight: 74406.8 
 
Theoretical pI: 5.43 
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4.4.17 Isolation of [35S]-methionine-labeled His×6-GMAP-210 with Ni(II)-loaded 
nanoparticles 
The Ni(II)-loaded nanoparticles (10 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and binding buffer (3×50 μL).  The washed nanoparticles were incubated with 5 μL of 
TNT reaction mixture in 100 μL of binding buffer for 60 minutes at 4 °C.  The nanoparticles 
were washed and the bound protein eluted according to the procedures detailed above. All 
the fractions including the remaining nanoparticles were transferred to scintillation vials for 
radioactivity measurements using a liquid scintillation counter.  Protein isolation using 
commercial magnetic agarose beads (Qiagen) was performed according to the manufacturer’s 
instructions, and scintillation counts were measured as mentioned above. 
 
4.4.18 Expression of His×6-UGT from cultured 293T cells 
The cDNA corresponding to the open reading frame of C. elegans UGT was 
amplified from a C. elegans cDNA library (Invitrogen) using high fidelity Platinum Pfx DNA 
polymerase (Invitrogen) and sequence-specific primers with CACC at the 5’ end of the 
forward primer. The full-length cDNA was gel purified and subcloned into the 
pcDNA3.1D/V5-His TOPO vector (Invitrogen) according to the manufacturer’s instructions. 
The resulting gene-containing plasmid was confirmed by PCR and sequence analysis. 
293T cells were cultured in Dulbecco’s Minimal Essential Media (DMEM, Gibco) 
supplemented with 10% Fetal Bovine Serum (FBS, Sigma), 1% L-glutamate (Gibco), and 
1% Penicillin/Streptomycin.  Cell culture was maintained at 37 °C with 5% CO2. On the day 
of transfection, the pre-formed UGT plasmid DNA-Lipofectamine complex (500 µL) was 
added directly to each well.  Cells were incubated at 37 °C in 5% CO2 for 4 hours. 
173 
 
Afterwards, the media was changed and 2 mL of fresh DMEM (with 10% FBS and 1% L-
glutamate) was added.  After incubation at 37 °C in a 5% CO2 incubator for a total of 24 
hours to allow protein expression, cells were harvested and lysed using a commercial 
extraction buffer (Biovision).  Intact cells were removed by centrifugation and the 
supernatants were cleared at 21,000×g for 15 minutes at 4 °C. Levels of protein expression 
were assessed by separation on SDS-PAGE gels, followed by Western blotting onto 
nitrocellulose membranes (Amersham Pharmacia), and probing with anti-V5 antibody 
(Invitrogen). The lysates that were prepared were used for binding studies. 
 
C. elegans UGT (C-HisX6-tagged) properties: 
10 20 30 40 50 
MLLRILTFLA VCQVTTSHKI LMFSPTASKS HMISQGRIAD ELANAGHEVV 
60 70 80 90 100 
NFEPDFLNLT DKFVPCKKCR RWPVTGLNNY KFKKIQNGLS GDVFQQSSIW 
110 120 130 140 150 
SKIFNTDSDP YQDEYTNMCE EMVTNKELIE KLKKEKFDAY FGEQIHLCGM 
160 170 180 190 200 
GLAHLIGIKH RFWIASCTMS VSMRDSLGIP TPSSLIPFMS TLDATPAPFW 
210 220 230 240 250 
QRAKNFVLQM AHIRDEYRDV VLTNDMFKKN FGSDFPCVEF LAKTSDLIFV 
260 270 280 290 300 
STDELLEIQA PTLSNVVHIG GLGLSSEGGG LDEKFVKIME KGKGVILFSL 
310 320 330 340 350 
GTIANTTNLP PTIMENLMKI TQKFKDYEFI IKVDKFDRRS FDLAEGLSNV 
360 370 380 390 400 
LVVDWVPQTA VLAHPRLKAF ITHAGYNSLM ESAYAGVPVI LIPFMFDQPR 
410 420 430 440 450 
NGRSVERKGW GILRDRFQLI KDPDAIEGAI KEILVNPTYQ EKANRLKKLM 
460 470 480 490 500 
RSKPQSASER LVKMTNWVLE NDGVEELQYE GKHMDFFTFY NLDIIITAAS 
510 520 530 540 550 
IPVLIFIVLR ISNISIITSS PKNKKDKGQD NSADIQHSGG RSSLEGPRFE 
560 570    
GKPIPNPLLG LDSTRTGHHH HHH   
 
Molecular weight: 64722.7 daltons 
Theoretical PI: 8.03 
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4.4.19 Isolation of His×6-UGT from cultured 293T cells using Ni(II)-loaded 
nanoparticles 
To purify the His×6-UGT expressed in 293T cells, the pre-washed, Ni(II)-loaded 
nanoparticles (10 μL; 16.3 mg/mL) were incubated with 50 μL of cleared crude cell lysate 
(~4 μg/μL total protein) in 50 μL of binding buffer for 15 minutes at 4 °C.  After washing 
nanoparticles three times using 50 μL of binding buffer, the bound proteins were eluted using 
15 μL of elution buffer. Aliquots of each fraction were loaded to an SDS-PAGE for 
separation. The protein was detected by Coomassie blue staining. 
 
4.4.20 Iron oxide nanoparticle surface modification with mono-NTA Ni(II) chelate 
One mL of iron oxide magnetic nanoparticles suspension (16.3 mg/mL) was added to 
ligand 8 (0.5 mL of a 10 mg/mL MeOH solution diluted by 1.25 mL dH2O of pH 4).  The 
two layers were sonicated for 1 hour, and repeatedly washed with n-hexanes, then methanol 
until the nanoparticles were readily dispersed in dH2O.  Using a magnet, the nanoparticles 
were collected and placed in 2 mL of dH2O.  The mono-NTA modified nanoparticles (0.5 
mL) were placed in 1M NiCl2 solution and sonicated for 1 hour.  The divalent Ni(II)-loaded 
nanoparticles were stored in the NiCl2 solution before use. 
 
4.4.21 Isolation of His-Ubiquitin C-terminal Hydrolase L-1, mouse recombinant (6xHis-
UCH-L1) with Ni(II)-loaded nanoparticles 
The Ni(II)-loaded nanoparticles (10 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and wash buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM 
imidazole, pH 8.0).  The washed nanoparticles were placed in 40 μL of wash buffer and 10 
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μL of 6xHis-UCH-L1 (1 μg 6xHis-UCH-L1/1 μL dH2O) and incubated for 60 minutes at 4 
°C.  Using a centrifuge and magnet, the supernatant was collected and nanoparticles washed 
in 50 μL aliquots (FT, W1, W2, W3).  After W3, 50 μL of elution buffer (50 mM phosphate 
buffer system, 300 mM NaCl, 250 mM imidazole, pH 8.0) was added and rotated for 10 
minutes at 4 °C.  Nanoparticles were collected in 50 μL aliquots (E1, E2).  Nonspecifically 
bound protein was released from the nanoparticles by boiling at 95 °C for 4 minutes.  The 
volumes of the aliquots were reduced for analysis by SDS-PAGE (12.5% separation gel, 
180V, 50 min).  The SDS-PAGE gel was stained using Coomassie Blue overnight. 
 
4.4.22 Isolation of His-Ubiquitin, human recombinant (6xHis-Ub) with Ni(II)-loaded 
nanoparticles 
The Ni(II)-loaded nanoparticles (10 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and wash buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM 
imidazole, pH 8.0).  The washed nanoparticles were placed in 40 uL of wash buffer and 10 
uL of 6xHis-Ub (1 μg 6xHis-Ub/1 μL dH2O) and incubated for 60 minutes at 4 °C.  Using a 
centrifuge and magnet, the supernatant was collected and nanoparticles washed in 50 μL 
aliquots (FT, W1, W2, W3).  After W3, 50 μL of elution buffer (50 mM phosphate buffer 
system, 300 mM NaCl, 250 mM imidazole, pH 8.0) was added and rotated for 10 minutes at 
4 °C.  Nanoparticles were collected in 50 μL aliquots (E1, E2).  Non-specifically bound 
protein was released from the nanoparticles by boiling at 95 °C for 4 minutes.  The volumes 
of the aliquots were reduced for analysis by SDS-PAGE (12.5% separation gel, 180V, 50 
min).  The SDS-PAGE gel was stained using Coomassie Blue overnight.   
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4.4.23 Isolation of Endoproteinase GluC, (6xHis-EndoGluC) with Ni(II)-loaded 
nanoparticles 
The Ni(II)-loaded nanoparticles (10 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and wash buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM 
imidazole, pH 8.0).  The washed nanoparticles were placed in 40 μL of wash buffer and 20 
μL of 6xHis-EndoGluC (1 μg 6xHis-EndoGluC/2 μL dH2O) and incubated for 60 minutes at 
4°C.  Using a centrifuge and magnet, the supernatant was collected and nanoparticles washed 
in 50 μL aliquots (FT, W1, W2, W3).  After W3, 50 μL of elution buffer (50 mM phosphate 
buffer system, 300 mM NaCl, 250 mM imidazole, pH 8.0) was added and rotated for 10 
minutes at 4 °C.  Nanoparticles were collected 50 μL aliquots (E1, E2).  Non-specifically 
bound protein was released from the nanoparticles by boiling at 95 °C for 4 minutes.  The 
volumes of the aliquots were reduced for analysis by SDS-PAGE (12.5% separation gel, 
180V, 50 min).  The SDS-PAGE gel was stained using Coomassie Blue overnight.   
 
4.4.24 Isolation of human recombinant His×6-caspase 3 (His×6-huCsp3) with Ni(II)-
loaded nanoparticles 
 The Ni(II)-loaded nanoparticles (1 μL; 16.3 mg/mL) were washed in dH2O (3×50 
μL) and wash buffer (3×50 μL; 50 mM phosphate buffer system, 300 mM NaCl, 10 mM 
imidazole, pH 8.0).  The washed nanoparticles were placed in 45 uL of wash buffer and 5 uL 
of 6xHis-huCsp3 (1X) and incubated for 60 minutes at 4 °C.  Using a centrifuge and magnet, 
the supernatant was collected and nanoparticles washed in 50 μL aliquots (FT, W1, W2, 
W3).  After W3, 50 μL of elution buffer (50 mM phosphate buffer system, 300 mM NaCl, 
250 mM imidazole, pH 8.0) was added and rotated for 10 minutes at 4°C.  Nanoparticles 
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were collected in 50 μL aliquots (E1, E2).  Non-specifically bound protein was released from 
the nanoparticles by boiling at 95 °C for 4 minutes.  Aliquots are analyzed by SDS-PAGE 
(12.5% separation gel, 180V, 50 min).  The SDS-PAGE gel was stained by silver staining. 
 
4.4.25 Activity Assay of human recombinant His×6-caspase 3 (His×6-huCsp3) eluted 
from Ni(II)-loaded nanoparticles 
 Eluted protein activity was measured using a commercially available (Biovision) 
caspase 3 fluorometric substrate.  Nanoparticle eluted His×6-caspase 3 (10 μL from 50 μL 
eluted volume) was incubated with 50 μM DEVD-AFC (Asp-Glu-Val-Asp-AFC) substrate in 
provided reaction buffer (50 μL) containing 10 mM DTT.  Multi-well fluorescence plate 
reader was set for excitation at 400 nm and emission at 505 nm and incubation temperature 
of 37ºC.   
 
4.4.26 Activity Assay of recombinant mouse His×6-Endostatin (His×6-rmES) eluted 
from Ni(II)-loaded nanoparticles 
A previously published protocol is used to determine apoptotic activity of eluted 
Hisx6-rmES.18  Briefly, cow pulmonary artery endothelial (C-PAE) cells are maintained in 
DMEM containing 2% FCS and 3 ng/mL bFGF.  Cells are treated with Hisx6-rmES directly 
eluted from Ni(II)-loaded nanoparticles (10 μg/mL).  As a negative control, cells are treated 
with an equivalent volume of elution buffer.  Cells are collected by trypsinization and 
washed twice with cold phosphate buffered saline (pH 7.4) before resuspension in binding 
buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2).  Cells are incubated with 
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Annexin V-PE per manufacturer’s protocol.  Stained cells are analyzed using confocal 
fluorescence microscopy. 
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